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During the past two decades, the identification of new sci-
entific developments to improve outcomes in gastrointestinal
disorders has been attractive to many researchers. Phar-
maceutical industries are now more motivated to intro-
duce novel therapeutic remedies in the treatment of gas-
trointestinal disorders. Such disorders have increased at an
exponential rate in various patient communities and both
natural and synthetic compounds have been investigated for
their potential biological activity in the treatment of these
gastrointestinal disorders.
Several interesting works were assessed in this special
issue. Amongst them five articles were chosen based on their
critical findings in gastrointestinal disorders.
The effects of rikkunshito on the decrease in food intake
were assessed after induction of stress in mice and showed
improvement in the decrease of food intake probably via
serotonin 2B receptor antagonism of isoliquiritigenin. In
another work, the preventive effect of inositol hexaphosphate
extract of rice bran on colon cancer was assessed. The results
showed significant reduction in the expression of 𝛽-catenin
andCOX-2 in colon tumors.The Schiff basemetal derivatives
also may enhance the expression of HSP70 and suppress the
expression of BAX proteins in an acute hemorrhagic gastric
ulcer model. Another animal study assessed the hepatopro-
tective activity of the ethanolic extract of rhizomes of Z. offic-
inale against thioacetamide-induced hepatotoxicity in rats.
The floating dosage form of an anticancer drug was prepared
in another study entitled “Preparation and Characterization
of aGastric FloatingDosage Formof Capecitabine.”Thework
characterized the sustained release tablet in terms of total
floating time, dissolution, friability, hardness, drug content,
and weight uniformity to compare the prepared formulation
with the commercial tablet in terms of drug release, and to
evaluate the stability of the formulation.
By presenting these articles, we hope that this issue incor-
porates new scientific evidence and emerging developments
as the basis of rational treatment in medicinal practice using
novel therapeutics (natural or synthetic compounds) in the
treatment of gastrointestinal disorders.
Mahmood Ameen Abdulla
Ibrahim Banat
Patrick Naughton
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Zingiber officinale is a traditional medicine against various disorders including liver diseases.The aim of this study was to assess the
hepatoprotective activity of the ethanolic extract of rhizomes of Z. officinale (ERZO) against thioacetamide-induced hepatotoxicity
in rats. Five groups of male Sprague Dawley have been used. In group 1 rats received intraperitoneal (i.p.) injection of normal saline
while groups 2–5 received thioacetamide (TAA, 200mg/kg; i.p.) for induction of liver cirrhosis, thrice weekly for eight weeks.
Group 3 received 50mg/kg of silymarin.The rats in groups 4 and 5 received 250 and 500mg/kg of ERZO (dissolved in 10% Tween),
respectively. Hepatic damage was assessed grossly and microscopically for all of the groups. Results confirmed the induction of
liver cirrhosis in group 2 whilst administration of silymarin or ERZO significantly reduced the impact of thioacetamide toxicity.
These groups decreased fibrosis of the liver tissues. Immunohistochemistry assessment against proliferating cell nuclear antigen did
not show remarkable proliferation in the ERZO-treated rats when compared with group 2. Moreover, factions of the ERZO extract
were tested on Hep-G2 cells and showed antiproliferative activity (IC
50
38–60 𝜇g/mL). This study showed hepatoprotective effect
of ERZO.
1. Introduction
Ginger or Zingiber officinale (family: Zingiberaceae) is a
perennial reed-like plant with annual leafy stems. The plant
is about a meter tall. The fragrant perisperm of Zingiber-
aceae is used as sweetmeats by the Bantu tribe [1]. Ginger
is traditionally used as a common condiment for various
foods and beverages such as soup, ginger ale, ginger bread,
ginger snaps, parkin, ginger biscuits, and speculoos. Ginger
rhizomes contain a number of pungent constituents and
active ingredients [2].The steam distillation of ginger powder
is used to produce ginger oil and contains high amount of
sesquiterpene hydrocarbons, predominantly zingiberene [3].
Gingerol is of the major pungent compounds in ginger and
can be altered to shogaols, zingerone, and paradol [4] which
takes part in several activities such as hepatoprotective [5],
antiparasitic [6], antiflarial [7], antimicrobial [8], antidiabetic
[9], and radioprotective [10]. Ginger also has a potential
remedy against cardiovascular disease [11] and can prevent
the development of morphine analgesic tolerance and phys-
ical dependence in rats [12]. The plant contains high level
of total phenolic and flavonoid, responsible for its high
antioxidant activities [13] (for reviews see [14, 15]).
Liver disease is still a worldwide health problem. It devel-
ops in about one-third of patients with chronic liver diseases
[16] with considerable level of morbidity and mortality [17].
Liver cirrhosis is an irreversible process characterized by
excess extracellular matrix (ECM) deposition in the liver
accompanied with scar formation and destruction of the
liver architecture [18]. During liver cirrhosis, the normal
tissue is replaced with the scar tissue, which can block the
blood flow of the liver. Liver cirrhosis also attenuates the
liver’s functions. The liver by itself is able to regenerate the
damaged parts, but, during end-stage cirrhosis, the liver
is not capable of renovating the damaged cells. Etiology of
the liver cirrhosis has a wide spectrum including viruses,
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toxins, drugs, and life style [19]. Despite several efforts in
drug discovery, treatment for liver cirrhosis is still a concern.
In fact complementary and alternative medicine is one of
the promising resources for treatment of liver cirrhosis. In
traditional remedies herbal drugs have been used for the
treatment of liver ailments. Many medicinal plants have been
introduced with hepatoprotective potential such as Vitex
negundo [20], Boesenbergia rotunda [21], Phyllanthus niruri
[22], Ipomoea aquatic [23], and Orthosiphon stamineus [24].
The phytochemicals phenolic compounds exhibit antioxidant
properties that scavenge the free radicals and ROS [25].
Antioxidant activity is important in the treatment of liver
cirrhosis [26, 27]. Thioacetamide (TAA) is a hepatotoxic
chemical and is widely used in induction of hepatic necrosis.
Moreover, thioacetamide causes oxidative stress during its
metabolism by microsomal CYP2E1. These effects together
cause acute hepatitis which consequently leads to apoptosis
of liver cells. Several phytochemicals have been reported in Z.
officinalewith hepatoprotective activity. For instance, in liver,
cineole may inhibit CYP2E1 [28] and tocopherol and hepa-
tocyte lipid peroxidation [29]. Inhibition of active caspase-
3, capsaicin, possesses hepatoprotective effect through its
antioxidant and free radical scavenging mechanisms [30].
Hepatoprotective activity of the ethanolic extract of rhizomes
of Z. officinale (ERZO) has not been reported specifically.
Thus, the present study was to assess the hepatoprotective
effect of ERZO against TAA-induced liver cirrhosis in rats.
2. Materials and Methods
2.1. Chemicals. In this study we used TAA (Sigma-Aldrich,
Germany) for induction of liver cirrhosis in the rats. Sily-
marin, a standard drug, was purchased from International
Laboratory USA. Ethanol (95%; industrial graded; R&M
chemical, UK) and 10% Tween-20 (Merck, Germany), con-
centrated formalin (38–40%; Merck, Germany), Di-natrium
hydrogenphosphat (Merck, Germany), sodium dihydrogen
phosphate monohydrate (Sigma-Aldrich, Germany), toluene
(Merck, Germany), xylene (BDH Laboratory supplies, Eng-
land), and other ordinary laboratory materials were also
obtained for this experiment.
2.2. Preparation of the Plant Extract. Fresh rhizome of the
plant was purchased from a commercial company (Ethno
Resources Sdn Bhd, Selangor,Malaysia) andwas identified by
the voucher specimen deposited at the Herbarium of Rimba
Ilmu, Institute of Science Biology, University of Malaya. The
rhizome was dried and ground into fine powder using an
electrical blender. Fine powder (100 g) was homogenized
in ethanol (95%; 500mL) and left in a conical flask at
room temperature for 3 days. Then, the mixture was filtered
through a fine muslin cloth and a filter paper (Whatman
No. 1). Using the Eyela rotary evaporator (Sigma-Aldrich,
USA) the extract became concentrated. The extract was then
lyophilized and yielded ERZO. Tween-20 (10%) was used to
dissolve the extract in the concentrations of 50mg/mL and
100mg/mL. In this study doses of 250mg/kg and 500mg/kg
were considered for the oral administration of ERZO.
Liquid-liquid partitioning was also performed on the
crude ERZO. Briefly, the extract was reconstituted with
distilled water (150mL × 3) to form a suspension. Then it
partitioned with n-hexane (200mL × 3), chloroform (200mL
× 3), and butanol (200mL × 3) to obtain soluble fractions of
n-hexane, chloroform, and butanol.The fractions weremixed
well, inverting the whole separation funnel. The suspension
was allowed to be separated overnight. For each solvent, the
separation was performed thrice. The organic fractions were
pooled and the same procedures were performed to yield the
respective fractions. Each dried fractionwas then dissolved in
DMSO (0.5%) in different concentrations for the cell culture
experiment.
2.3. Animal Experiments. The study was approved by the
ethics committee for animal experimentation, Faculty of
Medicine, University of Malaya, Malaysia, and the Ethic no.
PM/07/05/2011/MMA (a) (R). All animals received human
care according to the criteria outlined in the “Guide for
the Care and Use of laboratory Animals” prepared by the
National Academy of Sciences and published by the national
Institute of health. The rats were provided from the Exper-
imental Animal House, Faculty of Medicine, University of
Malaya. The animals were kept at 25 ± 2∘C (humidity, 50–
60%) with 12 h light/dark cycle.
2.4. Acute Toxicity Test. The toxicity of the ERZO was
evaluated in Sprague Dawley rats. The animals were treated
with two distinct doses of ERZO. The animals were given
standard rat pellets and tap water ad libitum. Thirty-six rats
(18 males and 18 females), weighed 150–180 g, were assigned
into 3 groups named control group (Tween-20 10% w/v;
5mL/kg), low dose group (ERZO, 2 g/kg), and high dose
group (ERZO, 5 g/kg). Prior to the dosing, the rats fasted
(food but water) overnight. Food was withheld for a further 3
to 4 hours after dosing. Each group received their respective
administration, orally. Then, the animals were observed high
frequently for 48 h for any sign of abnormality. The rats were
monitored for 14 days for any sign of toxicity. The animals
were sacrificed on the 15th day. Histological, hematological,
and serum biochemical parameters were also assessed [31].
2.5. Induction of Liver Injury. Thirty male SD rats (6–8 weeks
old; weighted 150–180 g) were obtained from the Experimen-
tal Animal House, Faculty of Medicine, University of Malaya.
The rats were randomly divided into 5 groups of 6 rats and
kept individually in a cage with wide-mesh wire bottom
(i.e., to prevent coprophagia during the experiment). Group 1
received i.p. injection of normal saline, thrice weekly, and oral
admonition of distilled water (5mL/kg), daily. Groups 2–5
were injectedwith 200mg/kgTAA (i.p.), thriceweekly as pre-
viously described [32]. Group 2 received oral administraion
of distilled water (5mL/kg). Group 5 received silymarin
(50mg/kg) as standard drug. Groups 4 and 5 were fed daily
with 250mg/kg and 500mg/kg of ERZO. The animals were
given water ad libitum. The body weights of the animals
were recorded weekly. The duration of the experiment was
8 weeks, according to the previous published work [24].
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The rats fasted for 24 h after receiving their respective
treatments.Then the animals were euthanized with ketamine
(30mg/kg) and xylazil (3mg/kg) anddiethyl ether inhalation.
For each rat, the abdomen and thoracic cavities were opened.
The internal organs were checked to be assured that the other
organs appear intact, microscopically. The liver was washed
with ice-cold normal saline and phosphate buffered saline
(PBS; pH 7.4).The organ was carefully dissected and assessed
grossly. The liver’s weight was recorded for each animal. The
tissues were preceded for immunohistology evaluations and
antioxidant activities. Blood was sampled through jugular
vein to assess the liver’s function.
2.6. Biochemical Parameters for Liver Function. Blood anal-
ysis was performed at the Clinical Diagnosis Laboratory
of University of Malaya Hospital. The main biochemical
parameters to assess the liver function were aspartate amino-
transferase (AST), alanine aminotransferase (ALT), alkaline
phosphatase (ALP), gamma glutamyl transferase (GGT),
globulin, conjugated bilirubin, total bilirubin, albumin, and
total protein.
2.7. Histopathology of Liver Tissues. Liver tissues were fixed
in 10% formalin. The fixed tissues were processed using an
automated tissue processing machine (Leica, Germany) and
were embedded in paraffin (Leica, Germany). Sections of
5 𝜇m thickness were prepared for each liver tissue. The sec-
tions were processed for hematoxylin and eosin (H&E) and
Masson’s Trichrome (MT) staining. Another set of sections
were prepared for immunohistochemistry study of the tissues
and mitotic indexing. The liver tissues were further assessed
for histopathological examination in a blinded fashion.
2.8. Immunohistochemistry and Mitotic Index. The sections
were heated at 60∘C for 60min in an oven (Venticell, MMM,
Einrichtungen, Germany). Then the tissues were deparaf-
finizedwith xylene.Thedehydrating stepwas performedwith
graded alcohols (absolute alcohol, 95% and 70% alcohol).
Antigen retrieval was performed with 10mM sodium citrate
buffer boiling in a microwave (Sanyo, Super Showe wave,
Japan). The sections were placed in TBS contained Tween-
20 (0.05%). The staining steps were performed according to
the manufacturer’s instructions (DakoCytomation, USA). In
short, endogenous peroxidase was quenched by peroxidase
blocking solution.Then the sectionswere incubatedwith pro-
liferating cell nuclear antigen (PCNA; 1 : 200), a biotinylated
primary antibodies, for 15min. Then, streptavidin-HRP was
added and incubated for 15min.The sections were incubated
with diaminobenzidine-substrate chromagen DAB for 5min.
The sectionswere then dipped inweak ammonia (0.037M/L).
Under light microscopy, PCNA positive tissues were stained
brown with blue background.
Cell proliferation was assessed though counting the
number of mitotic cells per high-power field (HPF) at the
magnification of 100x. For each slide 10 randomly selected
fields were counted. The mitotic index (MI) was defined as
the number of mitotic cells per 1,000 hepatocytes in paraffin-
embedded liver samples stained with H&E [33].
2.9. Superoxide Dismutase and Malondialdehyde in Liver Tis-
sue. The tissue samples were homogenized in cold 20mM
HEPES buffer (1mM EGTA, 210mM mannitol, and 70mM
sucrose; pH 7.2) using tephlon homogenizer (Polytron, Hei-
dolph RZR 1, Germany). The cell debris was separated by
centrifugation (Heraeus, Germany) at 1,500 g for 5min (4∘C).
The supernatantswere used for the estimation of SODactivity
(CaymanChemical Company, USA).TheMDA level was also
measured by thiobarbituric acid (TBARS) according to the
manufacturer protocol (Cayman Chemical Company, USA).
2.10. Cell Culture and Cytotoxicity of ERZO’s Fractions. There
were four different fractions, ZC, ZX, ZB, and ZW, represent-
ing chloroform, n-hexane, butanol, and aqueous fractions
of Z. officinale, respectively. A human liver carcinoma cell
line (Hep-G2) was obtained from American Type Culture
Collection (ATCC, USA). The 3-(4, 5-dimethylthiazol-2-yl)-
2, 5-diphenyl tetrazolium bromide (MTT assay) was used to
assess the number of viable cells which has been adapted to
measure the growth of cells in vitro. According to modified
protocol [34], the assay was adapted to 96-well cell culture
plates. Approximately, 5000 cells per well were seeded one
day before the experiment. Cell lines were cultured in RPMI-
1640 growth medium, supplemented with ERZO’s fractions
at different concentrations (3–200𝜇g/mL), 10% (v/v) sterile
fetal bovine serum (FBS, PAA Lab, Austria), 100mg/mL
streptomycin and 100U/mL penicillin (PAA Lab, Austria),
and 50mg/mL fungizone (Sigma Aldrich). The cultures were
incubated in 5% CO
2
incubator at 37∘C in a humidified
atmosphere. The cells were harvested by detaching the cells
from the culture flask using 1-2mL of trypsin after the flask
get confluent enough with the cells. The harvested cells were
transferred aseptically into 50mL sterile falcon tube and
washed with physiological buffer (pH 7.2) under spinning
at 1200 rpm for 2 minutes. The supernatant was discarded,
and the cells pellet was mixed with 1mL of sterile media and
was mixed to form a cell suspension. Harvested cells were
seeded into a 96-well culture plates at 100 𝜇L/well and allowed
to adhere overnight. ERZO’s fractions were predissolved
in dimethyl sulphoxide (DMSO) and diluted to different
concentration spanning from 3–200𝜇g/mL. Blank DMSO
was used as a control. Cells were incubated with the samples
(three wells on a plate for each concentration) for 24 to
72 h.Thereafter, 10 𝜇L of MTT (5mg/mL) (Sigma) was added
to each well and the plates were incubated at 37∘C for 4 h.
The media were then gently removed, and about 200mL of
DMSOwas added to dissolve the formazan crystals.TheMTT
formazan production was quantified spectrophotometrically
at 570 nmusing amicroplate reader (GF-M3000) for acidified
isopropanol and at 555 nm for DMSO. OD reading was
referenced to 700 nm to eliminate the background effect.
The percentage cell viability was calculated according to the
following equation:
Cell viability% = (
Abs
570
treated
Abs
570
untreated
) × 100. (1)
The IC
50
value was calculated using the line graph which was
drawn with % inhibition and sample concentration.
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Table 1: Effects of ERZO on body weight, liver weight, and liver
index.
Animal groups Body weight(gm)
Liver weight
(gm)
Liver index
(LW/BW%)
Normal
control 347 ± 6.65
b 10.33 ± 1.15 2.95 ± 0.22b
TAA control 172 ± 6.47a 12.61 ± 0.41 7.38 ± 0.36a
HD 500mg/kg 217 ± 3.44ab 10.14 ± 0.53b 4.66 ± 0.21ab
LD 250mg/kg 231 ± 8.76ab 11.78 ± 0.18 5.11 ± 0.19ab
Silymarin
50mg/kg 374 ± 8.16
b 10.66 ± 1.69 2.99 ± 0.32b
Data are expressed as mean ± SEM.Means among groups (𝑛 = 6 rats/group)
show significant difference.
b
𝑃 < 0.05 compared to TAA control group, and a𝑃 < 0.05 compared to
normal control group.
2.11. Statistical Analysis. In this study statistical analysis was
done using one-way analysis of variance (ANOVA) followed
by Bonferroni’s post hoc test (SPSS ver. 20; SPSS Inc., USA).
The 𝑃 value less than 0.05 was considered significant.
3. Results
3.1. Acute Toxicity Tests. The animals pretreated with ERZO
(2 g/kg and 5 g/kg) remained alive and did not manifest any
significant visible sign of toxicity within the experimental
period. There was no clinical and behavioral abnormality.
Histological assessment also confirmed that the extract is safe
in doses less than 5 g/kg within 15 days.
3.2. Liver Injury and the Effects of ERZO on Liver. Figure 1
shows gross appearance of the liver for each group. Liver
in all of the groups except group 2 possessed generally
smooth surfaces without significant irregularities or sign of
nodules. Table 1 lists the body weight and the liver weight
for each rat during the experiment. Group 1 demonstrated
a normal growth pattern for healthy rats. Administration
of TAA to group 2 lowered the body weight dramatically.
The administration of ERZO (250mg/kg and 500mg/kg) was
comparable with the effects observed in group 3 (silymarin
treated group).
3.3. Biomedical Parameter for Liver Function. According to
Tables 2 and 3, group 2 exhibits the highest levels of ALP, ALT,
AST, GGT, globulin, total bilirubin, and conjugated bilirubin
but albumin and total protein were the lowest among the
groups. ERZO (250mg/kg) showed that the level of ALP,
ALT, AST, GGT, globulin, total bilirubin, and conjugated
bilirubin were reduced significantly, whilst albumin content
was significantly elevated. In these groups, ERZO could
significantly restore the biochemical parameters to the levels
comparable with silymarin (the standard drug).
3.4. Histopathological Study. A histological image is shown
in Figure 2. Regular cellular architecture with distinct nor-
mal plates of hepatocytes separated by sinusoidal capillaries
and central vein was remarkable in group 1 (Figure 2(a)).
In TAA control group (group 2), the liver was enlarged
with numerous micro- and macronodules accompanied with
disrupted cellular architecture due to the presence of regen-
erating nodules. The liver was sectioned by fibrous septa
extending from the central vein to portal triad. The liver
in group 2 showed extensive hepatic damage with necrosis
and severe proliferation of bile duct. Moreover, there were
microvesicular and macrovesicular centrilobular type fatty
changes. Intense inflammation consisting of granulocytes
and mononuclear cells around the central vein and in portal
areas and congestion appeared to be significant. The livers
in groups 3–5 showed a relative protection against the
hepatic lesions induced by TAA. There was less disruption
of the hepatic cellular structure with mild fibrotic septa.
Lymphocyte infiltration in these groups was not significant.
They also showed occupied region of the liver by regenerative
parenchyma nodules surrounded by septa of fibrous tissue
with a remarkable increase in fat storing cells, Kupffer cells,
and bile ductules (Figures 2(c), 2(d), and 2(e)).
Masson’s trichrome staining was performed to evaluate
the degree of fibrosis. As shown in Figure 3(a), liver section
from group 1 had no collagen deposition. Group 2 showed
proliferation of bile duct with dense fibrous septa and
increased deposition of collagen fibers around the congested
central vein, which indicate a severe fibrosis (Figure 3(b)).
The rat treated with 250mg/kg and 500mg/kg of ERZO
showed less fibrous septa and irregular regenerating nodules
(Figures 3(d) and 3(e)). The collagen deposition patterns
appeared comparable among groups 3–5.These observations
confirmed the hepatoprotection activity of ERZO.
3.5. Regulation of PCNA and Mitotic Index. Using immuno-
histochemical staining against PCNA and mitotic index, the
proliferating cells were highlighted in the liver tissue sections
(Figure 4 and Table 4). Normal hepatocytes as appeared in
group 1 did not have PCNA positive cells. Moreover, this
group did not possess significant number of mitotic cells.
Similarly, group 3 had no sign of PCNA staining. In compari-
son, group 2 showed upregulation of PCNA as a proliferative
factor for the renovation of the damage tissues caused by
TAA. Administration of ERZO significantly declined the
mitotic index with low level of PCNA.
3.6. SOD and MDA Content of Liver Homogenate. The
antioxidant activity for group 2 showed that SOD was sig-
nificantly reduced when compared with group 1. The treated
groups with ERZO (250mg/kg and 500mg/kg) or silymarin
restored the SOD level significantly (Figure 5). MDA level
of liver homogenate was significantly high in group 2 but
administration of ERZO considerably lowered the level of
MDA. These results were comparable with the silymarin-
treated group (Figure 6).
3.7. Cytotoxicity Effect of ERZO’s Fractions on Hep-G2. In
vitro evaluation of ERZO’s fractions against human liver
carcinoma cell line is presented in Table 5. It is observed that
ZX fraction at low concentration <50mg/mL has the highest
inhibition activity with corresponding 59% inhibition and
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(a) (b) (c)
(d) (e)
Figure 1: Gross morphology shows the effects of ERZO on thioacetamide TAA induced liver damage in rats. (a) Normal control group shows
a regular and smooth surface. (b) Animals treated with TAA show many micronodules (arrowhead) and macronodules in the liver (arrow).
(c) Animals treated with TAA+ silymarin showing normal smooth surface. (d) Animals treated with TAA+ERZO 250mg/kg and (e) animals
treated with TAA + ERZO 500mg/kg. Both low dose and high dose of ERZO were having normal smooth surface and nearly preserve the
liver normal anatomical shape and appearance.
(a) (b) (c)
(d) (e)
Figure 2: Micrograph presents the histopathological sections of the livers taken from rats in different experimental groups. (a) Normal
histological structure and architecture were seen in livers of the normal control group. (b) Severe structural damage and formation of
pseudolobules with thick fibrotic septa with proliferation of bile duct and centrilobular necrosis were present in the liver of the TAA control
group. (c) Mild inflammation but no fibrotic septa were depicted in the liver of the hepatoprotective rat treated with TAA + silymarin. (d)
Partially preserved hepatocyte and architecture with small area of necrosis and narrow fibrotic septa existed in the liver of the rat treated with
TAA + 250mg/kg of the ERZO. (e) Partially preserved hepatocyte and architecture with small areas of mild necrosis were observed in the
liver of the rat treated with TAA + 500mg/kg of the ERZO (H&E stain original magnification 10x).
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(a) (b) (c)
(d) (e)
Figure 3: Photomicrograph shows histopathological sections of the livers sampled from different experimental groups. (a) Normal control
group shows normal liver architecture. (b) TAA control group shows proliferation of bile duct, dens fibrous septa, and collagen fibers. (c) Rat
treated with TAA + silymarin shows minimal fibrous septa and collagen fibers. (d) Rat treated with TAA + 250mg/kg of the ERZO shows
minimal fibrous septa and irregular regenerating nodules. (e) Rat treated with TAA + 500mg/kg of ERZO shows minimal fibrous septa and
collagen fibers. Masson’s Trichrome stain (original magnification 10x).
(a) (b) (c)
(d) (e)
Figure 4: Photomicrograph shows histopathological sections of the livers sampled from different experimental groups using an anti-PCNA
antibody. (a) Normal control group was stained without adding the primary antibody and shows normal liver architecture with no signs of
PCNA expression. (b) TAA control group showed many hepatocytes nuclei positive for PCNA monoclonal antibody. (c) TAA + silymarin
treated rats with no expression of PCNA in hepatocytes. (d) TAA + 250mg/kg of ERZO and (e) TAA + 500mg/kg of ERZO group showed
nearly normal liver architecture with no signs of PCNA expression (immunohistochemistry, 10x).
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Table 2: Effect of TAA, silymarin, and ERZO on biochemical parameters in the serum of experimental rats.
Animal groups T. protein (g/L) Albumin (g/L) Globulin (g/L) T. bilirubin (umol/L) Conjugated bilirubin(umol/L)
Normal control 68.67 ± 1.4b 12.83 ± 1.70b 54.50 ± 0.54b 2.66 ± 0.5b 1 ± 0.00b
TAA control 60.83 ± 0.47a 7.83 ± 0.40a 68.66 ± 3.44a 9 ± 0.21a 5.3 ± 0.00a
HD 500mg/kg 67.66 ± 0.41 12 ± 0.63b 54.16 ± 1.72b 5 ± 1.26a 3 ± 0.22ab
LD 250mg/kg 65.33 ± 0.33 11.50 ± 1.04b 51.50 ± 2.85b 7.33 ± 1.21a 3.5 ± 0.61a
Silymarin 50mg/kg 67.33 ± 0.95b 11.83 ± 1.83b 54.33 ± 3.61b 5.66 ± 1.86 3 ± 0.36a
Data are expressed as mean ± SEM. Means among groups (𝑛 = 6 rats/group) show significant difference.
b
𝑃 < 0.05 compared to TAA control group, and a𝑃 < 0.05 compared to normal control group.
Table 3: Effects of pretreatment with TAA, silymarin, and ERZO on serum liver biomarkers of experimental rats.
Animal groups ALP (IU/L) ALT (IU/L) AST (IU/L) GGT (IU/L)
Normal control 100.67 ± 4.96b 64 ± 1.26b 174.5 ± 8.11b 5 ± 0.00b
TAA control 243.83 ± 18.33a 209.83 ± 5.23a 322.16 ± 6.17a 12 ± 0.00a
HD 500mg/kg 119.67 ± 3.72ab 63.83 ± 7.25b 180.83 ± 1.94b 6.67 ± 0.55ab
LD 250mg/kg 218.83 ± 16.58a 82.5 ± 3.09ab 227.83 ± 4.62b 6.83 ± 0.16b
Silymarin 50mg/kg 132.66 ± 10.44b 70.3 ± 4.92b 184.33 ± 7.9b 7 ± 0.00ab
Data are expressed as mean ± SEM. Means among groups (𝑛 = 6 rats/group) show significant difference.
b
𝑃 < 0.05 compared to TAA control group, and a𝑃 < 0.05 compared to normal control group.
Table 4: Effects of pretreatment with TAA, silymarin, and ERZO on
mitotic index.
Animal groups Mitotic index
Normal control 0
TAA control 2.8 ± 1.15a
HD 500mg/kg 0.5 ± 0.16
LD 250mg/kg 0.7 ± 0.08
Silymarin 50mg/kg 0.4 ± 0.02
Data are expressed as mean ± SEM.Means among groups (𝑛 = 6 rats/group)
show significant difference; a𝑃 < 0.05 compared to normal control group.
Table 5: Antiapoptotic efficacy of ERZO’s fractions by MTT assay
on Hep-G2 cell line.
ERZO fractions IC50 (𝜇g/mL)
ZX 38
ZC 42
ZB 60
ZW >200
IC
50
of 38 𝜇g/mL. However, beyond 50 𝜇g/mL, ZB fraction
showed the lowest efficacy with corresponding 67% inhibi-
tion and IC
50
of 60𝜇g/mL. In comparison to ZB fraction,
ZC fraction was observed to be more potent on Hep-G2 cell
line achieving a maximum inhibition of about 92% and IC
50
of 42𝜇g/mL.The percentage inhibition appeared to continue
to increase with increasing concentration up to 200𝜇g/mL.
However, the aqueous fraction ZW performance was found
to have an IC
50
> 200𝜇g/mL.
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Figure 5: Effect of ERZO on SOD level in the liver tissue. Data are
expressed as mean ± SEM. Means among groups (𝑛 = 6 rate/group)
show significant difference, ∗𝑃 < 0.05 compared to TAA control
group, and ∗∗𝑃 < 0.05 compared to normal control group.
4. Discussion
Several models have been introduced in induction of hepatic
injuries [35]. TAA, a most common agent used for induction
of liver cirrhosis in animal studies, converts into a toxic
reactive metabolite named N-acetylp-benzoquinone imine
(NAPBI) and halogenates free radical in hepatic cytochrome
p450 [36]. A single dose of TAA causes centrilobular necrosis
and subsequent regenerative response in animals [37]. Oral
administration of TAA to rodents causes apoptosis and
necrosis. In fact, thioacetamide can cause liver cirrhosis
and hepatocarcinoma [38, 39], hepatocellular carcinomas,
hepatocellular neoplasms, bile duct, and cholangiocellular
neoplasms [34]. TAA is specific for the liver and regiospecific
for the perivenous hepatocytes with a long window period
between necrogenic effects and liver failure [37]. In this
study, acute toxicity test showed that ERZO was not toxic
<5mg/kg and did not cause any sign of toxicity or mortality
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Figure 6: Effect of ERZO on MDA level in the liver tissue. Data are
expressed as mean ± SEM. Means among groups (𝑛 = 6 rate/group)
show significant difference, ∗𝑃 < 0.05 compared to TAA control
group, and ∗∗𝑃 < 0.05 compared to normal control group.
within 14 days of the experiment. This observation was in
accordance with the previous studies on Z. officinale [40, 41].
Rats in group 2 showed hepatomegaly. The increased liver
weight/body weight ratio in TAA-treated animal was due
to the accumulation of fat and degeneration in the liver.
This result was in agreement with a previous report on the
increased liver weight/body weight ratio [42]. Our result
showed that ERZO could significantly accelerate the recovery
of the liver damage. Liver cirrhosis caused hepatomegaly
but in this experiment treatment with ERZO significantly
prevents the effect of TAA as previously described [24]. The
reduction of body weight seen in ERZO treatments might be
due to the reduction of hyperlipidemic [43].
TAA enhanced the levels of serum biochemical parame-
ters such as globulin, total bilirubin, and conjugated bilirubin
but lowered total protein and albumin as previously reported
[44].The serumbiochemical level forALT,AST, andALP is in
accordance with the extent of liver damage [45].These results
confirmed previous works [41, 44]. The elevation in AST
and ALT reflects hepatocellular injury while ALP is linked to
the GGT elevation [46]. ERZO reduced the level of ALP as
previously reported by Ajith et al. 2007 [47].
Histological evaluation showed protective effect of ERZO
against TAA-induced liver cirrhosis. TAA by its nature
induces liver cirrhosis in rats. A normal liver has a regular
and smooth surface, but in liver cirrhosis it appeared rough
and nodular with formations of micronodules and macron-
odules. In the histopathology evaluation, severe structural
damage, formation of irregular pseudolobules with dense
fibrotic septa, and proliferation of bile ducts in presence of
centrilobular and inflammatory cells were noticeable. The
treatment with silymarin and ERZO (in both doses) was
considerable. ERZO could enhance reconstitution of liver
structure from cirrhosis. The protection level of ERZO was
dosedependent as the treatment of 500mg/kg of ERZO had
more protective effect. Moreover, a remarkable reduction in
liver fibrosis was observed in ERZO (especially at 500mg/kg),
as previously confirmed [44, 48]. As Masson’s trichrome
staining showed, minimal reduction in collagen synthesis
was seen in ERZO-treated groups. In a healthy liver, no
significant collagen deposition was observed. The cytoplasm
of the cells appeared clear, with dilated central veins [49,
50]. Liver cirrhosis induced by TAA caused severe fibrosis
especially around bile ducts where dense fibrous septa and
high deposition of collagen fibers with distorted nuclei and
extensively vacuolated cytoplasm were considerable. The
standard drug, silymarin, reduced collagen deposition and
the cells architecture was resembled. Comparably, ERZO
showed a moderate deposition of collagen fibers, especially
in the dose of 500mg/kg. Our results confirmed previous
reports on the reduction of necrosis and fibrosis in hepatoxic
liver cells in response to phytochemical treatments [49, 50].
The inhibitory effect of ERZO on hepatic stellate cell
activation was confirmed by Lee et al. 2011 [51].
PCNA, also known as cyclin, is a nuclear protein syn-
thesized in G
1
/S-phase of the cell cycle and is related to
cell proliferative activity [52–54]. PCNA is polymerase S
accessory protein, essential for cellular DNA synthesis [54].
Liver cirrhosis showed upregulation of PCNA, indicating
extensive proliferation for the replacement of the damaged
tissues. Treatment with ERZO or silymarin significantly
reduced the expression of PCNA as previously reported [55].
The antioxidant test for SOD for the treated rats with ERZO
showed high level of activity in comparison with the TAA
control group (group 2). The SOD activity appeared similar
in both groups treated with ERZO or silymarin which con-
firmed the previously published work [47]. Reactive oxygen
species and nitric oxide are responsible for the induction
of hepatocytes apoptosis [56]. Administration of ERZO
significantly reducedMDA activity as previously observed in
adriamycin-induced model [57].
On evaluating the antiapoptotic efficacy, Hep-G2 cell line
was used in this analysis. n-Hexan fraction of ERZO proved
to be more potent on Hep-G2 cell line. On the other hand,
chloroform fraction of ERZO showed a moderate potency.
Butanol fraction of ERZO showed lower efficacy. However,
water fraction of ERZO was observed to show the lowest
inhibitory activity. In general, the observed efficacy could
probably be due to the phytochemical constituents of this
plant. The antioxidant action of Z. officinale has been pro-
posed as one of themajor possiblemechanisms for the protec-
tive actions of the plant against toxicity. It has been shown that
[6]-gingerol is endowed with strong antioxidant action both
in vivo and in vitro, in addition to strong anti-inflammatory
and antiapoptotic actions. Pretreatment with [6]-gingerol
reduced UVB-induced intracellular reactive oxygen species
levels, activation of caspases 3, 8, and 9, and Fas expression.
It also reduced UVB-induced expression and transactivation
of COX-2 [58].The hepatoprotective effect of ERZO is due to
its antioxidant potency [13] dominated by monoterpenoids
[59]. This could be due to the fact that flavonoids have the
ability to inhibit lipid peroxidation [5]. These data suggested
that ERZO is a very effective agent for the prevention of liver
cirrhosis.
5. Conclusion
In the present study, the hepatoprotective activity of ERZO
was explored in vitro and in vivo. Histology, ERZO slowed
down liver fibrosis progression and prevents the generation
of free radical induced by TAA, which provide an insight into
BioMed Research International 9
the mechanism of its biological action. According to these
data, Z. officinale ingestion is safe in humans and might be
a promising hepatoprotective agent.
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Schiff base complexes have appeared to be promising in the treatment of different diseases and disorders and have drawn a lot of
attention to their biological activities. This study was conducted to evaluate the regulatory effect of Schiff base metal derivatives on
the expression of heat shock proteins (HSP) 70 and BAX in protection against acute haemorrhagic gastric ulcer in rats. Rats were
assigned to 6 groups of 6 rats: the normal control (Tween 20 5% v/v, 5mL/kg), the positive control (Tween 20 5% v/v, 5mL/kg), and
four Schiff base derivative groups named Schiff 1, Schiff 2, Schiff 3, and Schiff 4 (25mg/kg). After 1 h, all of the groups received
ethanol 95% (5mL/kg) but the normal control received Tween 20 (Tween 20 5% v/v, 5mL/kg). The animals were euthanized after
60min and the stomachs were dissected for histology (H&E), immunohistochemistry, and western blot analysis against HSP70
and BAX proteins. The results showed that the Schiff base metal derivatives enhanced the expression of HSP70 and suppressed the
expression of BAX proteins during their gastroprotection against ethanol-induced gastric lesion in rats.
1. Introduction
Wide spectrum applications of the Schiff base in biological
systems have opened a new horizon in pharmaceutical
researches. Schiff bases are usually synthesized through the
condensation process of primary amines and active carbonyl
groups. Furthermore, indole derivatives have critical roles
in variety of biological activities. In novel therapeutics,
the development of hybrid molecules consisting different
pharmacophores in one frame may lead to remarkable phar-
macological effects. The coadministration of the moieties,
acting by different mechanisms, may have a synergistic effect
with higher activities [1]. The pharmacological activity of
Schiff bases metal complexes is solely attributed to the metal,
its ligands, or both. Two important factors such as maximum
thermodynamic stability and large degree of selectivity are
crucial in the design of Schiff base metal complexes or
ligands for pharmaceutical application. Various metal com-
plexes have been introduced for their potential therapeutic
applications. Possessing various biological activities, some
of the first row transition metals are important in metallo-
proteins.The chemistry of themetal complexes of Schiff bases
containing nitrogen and other donors is well described by
Tarafder and colleagues [2]. Various Schiff base complexes
have shown variety of properties such as anticancer [3–5],
antimicrobial, antifungal [6, 7], antiviral [8] and antioxidant,
and anti-inflammatory activity [9]; also see [10]. It is believed
that some complexes are more effective in metal complexes
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than free ligands [11]. Recent studies showed that Schiff base
complexes also have remarkable effects against peptic ulcer
[12–17].
Peptic ulcer is a result of imbalance between aggressive
factors and protective factors. Ethanol has been widely used
to induce acute hemorrhagic gastric lesions in animal model
studies. Ethanol as an aggressive factor can induce apoptosis
in the gastric mucosa. In both prokaryotic and eukaryotic
cells, these proteins are classified according to their size [18].
Small heat shock proteins with molecular mass between 15
and 30 kDa act as molecular chaperones in the unfolding
and refolding reactions [19, 20]. Heat shock proteins also
are important in the translocation of polypeptides across
mitochondria membranes [21], nucleus [22], and endoplas-
mic reticulum [23]. Upregulation of HSPs is a protective
mechanism in many biological systems. 70 kDa heat shock
protein (HSP70) mediates its biological roles through an
interaction with other proteins [24]. Several studies have
shown that HSP70 is a type of protein in variety of biological
systems. This protein could inhibit apoptosis [25], maybe
through its chaperone function stress-induced apoptosis
independent from the immune response [26]. This protein is
also important in proteins translocation across the nucleus
[22]. Heat shock proteins play a critical role in gastropro-
tection against acute hemorrhagic lesion of gastric mucosa.
Studies showed that gastric tissues produce HSP70 as a pro-
tective mechanism against ethanolic induced gastric lesions
[16, 27–29]. Tsukimi and Okabe reviewed that enhance in
expression of HSP70 is an important protective mechanism
in mucosal defence against ethanolic-induced lesions [30].
Several studies introduced variety of synthetic compounds
and natural products that enhanced the expression of HSP70
in protection of gastric tissue [16, 28, 29, 31]. BAX, a member
of Bcl-2 family, is a proapoptotic protein which induces
apoptosis [32] to maintain homeostasis. The cytosol in a cell
normally contains BAX protein but during apoptosis it
migrates to the mitochondria [33]. Ethanol produces reactive
oxygen species that increases the expression of BAX protein
and causes acute hemorrhagic gastric lesions [16, 27–29]. In
our previously published work, copper Schiff base complexes
caused a remarkable protection against ethanolic-induced
gastric ulcer [16]. The present article was to evaluate whether
Schiff bases metal derivatives enhance the expression of heat
shock proteins and suppress the expression of BAX proteins
in prevention of acute gastric lesion. The gastroprotective
properties of each Schiff base derivative complexes were not
the main focus in this work.
2. Materials and Methods
2.1. Preparation of Schiff Bases. Condensation between car-
bonyl group and amines is possible in different reaction
conditions and in different solvents [34]. The presence of
dehydrating agents normally favours the formation of Schiff
bases. Acid salts (usually MgSO
4
or Na
2
SO
4
) are commonly
employed as a dehydrating agent. Primary alcohols such as
ethanol are the main solvent for the preparation of Schiff
bases. Schiff bases have been purified by crystallizationmeth-
ods. Chromatography of Schiff bases on silica gel might cause
Table 1: Specifications of groups for first and second section of the
experiment.
Groups First section Second section
Normal group Tween 20(5% v/v), 5mL/kg Tween 20 (5% v/v), 5mL/kg
Positive group Tween 20(5% v/v), 5mL/kg Ethanol (95% v/v), 5mL/kg
Schiff 1 25mg/kg∗ Ethanol (95% v/v), 5mL/kg
Schiff 2 25mg/kg∗ Ethanol (95% v/v), 5mL/kg
Schiff 3 25mg/kg∗ Ethanol (95% v/v), 5mL/kg
Schiff 4 25mg/kg∗ Ethanol (95% v/v), 5mL/kg
∗Dissolved in Tween 20 (5% v/v) and orally given at the dose of 5mL/kg.
O
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Figure 1: Reaction pathway for the Schiff base derivative.
decomposition of the Schiff bases, through hydrolysis [35].
Stirring the crude reaction mixture in hexane or cyclohexane
can purify the Schiff base in these solvents [36]. Moderate
polar solvent, such as diethyl ether and dichloromethane,
might enhance the purity [37]. In general, Schiff bases are
stable solids and can be stored without many precautions
[35]. This type of compound is known as an imine or Schiff
base. Figure 1 illustrates the general structure of Schiff base
derivative. In this study, four Schiff base derivatives with
different metal groups named Schiff 1, Schiff 2, Schiff 3, and
Schiff 4 were tested to assess the expression levels of HSP70
and BAX proteins during their gastroprotective activity.
2.2. Animals. SpragueDawley (8–10weeks old, weighted 210–
230 g) rats were obtained from the Experimental Animal
House, Faculty of Medicine, University of Malaya. Animal
care and experimental procedures were performed in accor-
dance with the Guide for the Care and Use of Laboratory
Animals (National Institute ofHealth)with approval from the
committee for animal experimentation, Faculty of Medicine,
University of Malaya (ethic no. (ISB/30/05/2012/SG (R))).
They were maintained at ∼24∘C with free access to standard
laboratory pellet and water. 12 h before the experiment, the
animals’ access for food was restricted. Their access to water
was also restricted from 2 h before the experiment.
2.3. Animals Experiment. In this experiment, in addition to
two control groups, named the normal group (𝑛 = 6) and
the positive group (𝑛 = 6), the animals were assigned to four
Schiff base groups (Schiff 1, Schiff 2, Schiff 3, and Schiff 4)
of 6 rats. The experimental diagram shows specifications for
each group (Table 1). In brief, the experiment was divided
two sections (Sections 1 and 2). An hour interval was
introduced between the sections. In the first section, the
normal group and the positive group received 5mL/kg Tween
20 (5% v/v) while the other groups received 25mg/kg of
BioMed Research International 3
their respective Schiff base complexes (Schiff 1 to Schiff 4)
dissolved in Tween 20 (5% v/v). The animals received a
volume of 5mL/kg of their respective complexes.The animals
received 5mL/kg of ethanol (5% v/v) after 1 h but the normal
group received 5mL/kg of Tween 20 (5% v/v). The animals
were euthanized after 1 h and their stomachs were dissected
for further analysis.
Thegastric lesion indexingwas performed as described by
several works [38–41]. In brief, a dissectingmicroscope of the
lesion area (mm2) was measured.The index was calculated as
inhibition percentage, accordingly [29, 31].
2.4. Histological Observation. Gastric tissues were fixed in
buffered formalin (10% v/v) for 18 h and processed by a
tissue-processing machine (Leica, Germany). Sections of the
stomach were prepared on proper histological slides at a
thickness of 5𝜇m and proceeded to hematoxylin and eosin
(H&E) staining and immunohistochemical staining.
Immunohistochemistry staining was performed accord-
ing to the manufacturer’s protocol (DakoCytomation, USA).
Tissue sections were incubated with HSP70 (1 : 500) and
BAX (1 : 200) biotinylated primary antibodies. Streptavidin-
HRP (streptavidin conjugated to horseradish peroxidase) was
incubated as a secondary antibody. Under light microscope,
the secondary antibody appeared as brown stains.
2.5. Western Blotting. Stomachs of each rat were washed and
tissue homogenates were prepared with phosphate buffer
(50mM, pH 7 at∼4–8∘C).Thehomogenates were centrifuged
at 4000 rpm for 20min (4∘C) and the supernatant was
subjected for protein extraction using the lysis buffer (50mM
Tris-HCL pH 8.0, 120mM NaCl, 0.5% NP-40, 1mM PMSF),
Protein extract (25 g) was separated by SDS-PAGE (10%),
then transferred to a polyvinylidenedifluoride membrane
(Bio-Rad), and blocked with 5% nonfat milk in TBS-Tween
buffer 7 (0.12M Tris-base, 1.5M NaCl, 0.1% Tween 20).
The membrane was incubated with the antibodies (HSP70
(1 : 1000), BAX (1 : 1000), and 𝛽-actin 1 : 10,000; Cruz Biotech-
nology, USA) following incubation with horseradish perox-
idase conjugated secondary antibody. The bound antibody
was detectedwith peroxidase conjugated anti-rabbit antibody
(1 : 10,000) or anti-mouse antibody (1 : 10,000) followed by
chemiluminescence (ECL System) and exposed by autoradio-
graphy [42].
3. Results
3.1. Lesion Indexing. Gross appearance of luminal surface
of the stomach for each group that received the Schiff base
complexes showed significant protection when compared
with the positive group. However, the protection indexes
varied among the rats that received Schiff base complexes.
The protection index for Schiff 1 was 73.6% ± 5.50%; Schiff 2
68.06% ± 6.28%; Schiff 3 83.37% ± 6.85%; Schiff 4 79.83% ±
6.47%.
3.2. Histological Observation. Figure 2 shows the H&E stain-
ing of gastric tissue for each group. Histological evaluation
of gastric tissues showed that ethanol imposed extensive
acute haemorrhagic damages into gastric tissue of the positive
group. The mucosal and submucosal tissues were disrupted
by lesions. Edema was typically observable at the submucosal
layer with neutrophil migration. In the experimental groups
that received the Schiff base complexes, the damages were
significantly reduced when compared with the positive con-
trol group. The Schiff base complexes protected the mucosal
and submucosal tissues. The histology slides showed that
these groups possessedmoderate lesion and disruption of the
histological layers. Furthermore, the edema was remarkably
declined and neutrophil migration was negligible (Figure 2,
left column).
3.3. Immunohistochemistry. Immunohistochemistry study
showed the expression of HSP70 and BAX proteins in tissue
sections of the gastric tissues among the groups. Figure 2
shows the expression of HSP70 and BAX proteins (mid and
right columns, resp.) in different groups. Microscopic evalu-
ation of the gastric sections showed that acute haemorrhagic
gastric lesions induced by ethanol caused an increase in the
expression of BAX protein (Figure 2(f)) and decline in the
expression of HSP70 protein (Figure 2(e)). Oral administra-
tion of the Schiff base complexes enhanced the expression
of HSP70 protein (Figures 2(h), 2(k), 2(m), and 2(q)) and
suppressed the expression of BAX protein (Figures 2(i), 2(l),
2(o), and 2(r)). In Figure 2, the expression of these two
proteins is characterized by the brown colour staining of the
cytoplasm.
3.4. Western Blotting. Throughout the western blot analysis,
we conducted a comparable analysis of these proteins in the
tissue homogenates of each sample where the 𝛽-actin protein
was considered the loading control. The result showed that
HSP70 was significantly induced in those rats that received
the Schiff base complexes as compared with the positive
group (Figure 3). On the other hand, the expression of BAX
protein was suppressed when the animals received the Schiff
based complexes (Figure 3). These results confirmed the role
of Schiff base complexes in the regulation of certain proteins
as a protective mechanism.
4. Discussion
Ethanol intoxication caused extensive and acute haemor-
rhagic lesions on the luminal surface of the gastric tissue
and damaged the gastric layers. Previous studies showed that
such disruption caused decline in antioxidant properties of
the stomach and increased in neutrophil infiltration [16, 28,
29, 31]. These studies also confirmed that ethanol reduced
the expression of HSP70 protein but enhanced the regulation
of BAX protein. Antiulcer properties of several agents have
proven the importance of upregulation of HSP70 protein for
gastroprotection. For instance, Polygonum chinense aqueous
leaf extract and Mucuna pruriens at the dose of 250mg/kg
and 500mg/kg, respectively, showed the highest expression
level of HSP70 [28, 31]. Our previous study also confirmed
that Schiff base derived copper (II) significantly enhanced
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Figure 2: Microscopic study of gastric mucosa in rats (20x). Histological H&E staining of the gastric tissues (left column) and
immunohistochemistry (IHC) of HSP70 and BAX proteins (mid column and right column, resp.) are shown for different experimental
groups. Normal control group (1st row) shows intact gastric tissue with moderate presence of HSP70 and low presence of BAX. The ulcer
control group (2nd row) shows epithelial disruption with acute hemorrhagic lesions into the mucosa. Remarkable submucosa edema and
leucocyte penetration are noticeable. The presence of HSP70 is apparently suppressed while the BAX protein is considerably overwhelmed.
The Schiff base derivative complexes (3rd–6th rows) show considerable protection against the mucoepithelial disruption caused by ethanol.
The edema is not significant. The IHC of HSP70 and BAX shows that these proteins are meaningfully regulated by the Schiff base derivative
complexes. The presence of HSP70 in considerably increased when compared to either of the control groups while that of BAX proteins is
dramatically declined.
Schiff 1 Schiff 2 Schiff 3 Schiff 4Nor Pos
HSP70
BAX
𝛽-actin
Figure 3: Western blot assay against HSP70 and BAX mouse
monoclonal antibody. Corresponding 𝛽-actin blots are considered
as the loading control. Nor, the normal control group, Pos, the ulcer
control group.
the expression of HSP70 [16]. In all of these studies, the
enhancement ofHSP70 proteinwas parallel with the suppres-
sion of BAX protein.
In this study we assessed the protein expression levels
of HSP70 and BAX proteins when the animals were admin-
istered with different Schiff base complexes. Based on our
pilot study, the dose of 25mg/kg was the optimal dose for
its preventive properties. Moreover, to evaluate the biological
effect of Schiff base derivative complexes, all of the Schiff base
groups received the same dose (25mg/kg) of their respective
Schiff base complexes. The microscopic evaluation of the
stomach for each group showed that Schiff base complexes
remarkably increased the gastric protection against ethanol-
induced ulcers in rats. Although the protection level of
each Schiff base complexes did not appear to be similar,
they showed protective property for Schiff base derivative
complexes. This work mainly focussed on the expression
level of HSP70 and BAX proteins in the protection against
acute haemorrhagic gastric lesions. Histological examination
with H&E staining confirmed the protective effect of the
Schiff base complexes, accordingly. This study revealed that
the Schiff base complexes inhibited neutrophil infiltration
to the submucosal layer. Moreover, immunohistochemical
staining againstHSP70 andBAXproteins showed the effect of
the Schiff base complexes in enhancement of HSP70 protein
and suppression of BAX protein while the animals received
their respective administration of Schiff base complexes.
Western blot assay showed that the expression level of
HSP70 was enhanced, in the tissue homogenates, when the
rats received the respective administration of Schiff base
complexes in the first section of the experiment. Expectedly,
the expression level of BAX protein was suppressed upon
receiving Schiff base complexes.
5. Conclusion
Schiff base derivative complexes are among the promising
compounds with several biological properties. This study
was conducted to evaluate the expression level of HSP70
and BAX proteins in acute haemorrhagic gastric lesions in
rats administrated with Schiff base derivative complexes.The
Schiff base complexes showed direct relationship with the
expression level of HSP70 protein. They also showed that
they might suppress the expression of BAX protein as a
protective mechanism. Each Schiff base complexes showed
a different level of protection but all of them had the same
regulatory properties on the expression of HSP70 and BAX
proteins at the dose of 25mg/kg. Consistent with several
studies on gastroprotective complexes, Schiff base derivative
complexes showed prosperous protective potential through
protein regulation pathways. The immunohistochemistry
evaluation of gastric tissues showed the protein regulation in
situ which was confirmed by western blot assay accordingly.
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We investigated the effects of rikkunshito (RKT), a ghrelin signal enhancer, on the decrease in food intake after exposure to novelty
stress in mice. RKT administration (500mg/kg, per os) improved the decrease in 6 h cumulative food intake. In control mice, the
plasma acylated ghrelin levels significantly increased by 24 h fasting. In contrast, the acylated ghrelin levels did not increase by
fasting in mice exposed to the novelty stress. RKT administration to the novelty stress mice showed a significant increase in the
acylated ghrelin levels compared with that in the distilled-water-treated control mice. Food intake after administering serotonin
2B (5-HT2B) receptor antagonists was evaluated to clarify the role of 5-HT2B receptor activation in the decrease in feeding behavior
after novelty stress. SB215505 and SB204741, 5-HT2B receptor antagonists, significantly improved the decrease in food intake
after exposure to novelty stress. A component of RKT, isoliquiritigenin, prevented the decrease in 6 h cumulative food intake.
Isoliquiritigenin showed 5-HT2B receptor antagonistic activity in vitro. In conclusion, the results suggested that RKT improves the
decrease in food intake after novelty stress probably via 5-HT2B receptor antagonism of isoliquiritigenin contained in RKT.
1. Introduction
Stress is becoming a significant social problem [1, 2] and is
known to influence gastrointestinal function [3, 4].One of the
psychological stressors experienced in daily life is exposure to
social environmental changes, but no detailed investigation
regarding the effects of stress associatedwith this exposure on
feeding behavior has been conducted. The novelty-induced
hypophagia test measures the suppression of food intake by
exposure to a novel environment and is one of the few animal
tests of anxiety [5, 6].
Central 5-hydroxytryptamine (5-HT; serotonin) func-
tions by evoking fear and anxiety manifestations and
is involved in appetite regulation. Acute 5-HT depletion
decreases anxiety behavior that is measured by inhibition of
food intake during exposure to novel stimuli [7]. 5-HT
2C
receptor (5-HT
2CR) stimulation may decrease hunger [8,
9], and this type of receptor is expressed on corticotropin-
releasing factor (CRF) neurons in the hypothalamic paraven-
tricular nucleus and on proopiomelanocortin neurons in the
arcuate nucleus [10]. In addition, stimulation of 5-HT
2BRs,
which are distributed throughout the gastrointestinal system,
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negatively regulates eating behavior [11–13]. We previously
confirmed that novelty stress decreases food intake by acti-
vating bothCRF1R and 5-HT
2CR [14]. However, we have been
unable to clarify the role of 5-HT
2BR activation in decreased
food intake as a result of novelty stress.
Ghrelin is an orexigenic hormone produced in large
quantities in the stomach [15]. Peripheral ghrelin binds to
its specific growth hormone secretagogue receptor (ghrelin
receptor) localized at the end of the vagus nerve around
the stomach [16, 17]. Ghrelin secretion from the stomach is
regulated by particular subtypes of some neurotransmitters.
Activations of 5-HT
2BR and 5-HT2CR lead to a reduction
in the circulating ghrelin concentrations via a decrease in
ghrelin secretion in the stomach [13]. In mice exposed to a
novelty stress condition, plasma ghrelin levels decreased 3 h
after stress application, and acylated ghrelin supplementation
remedied this reaction [14].
Rikkunshito (RKT) is a Japanese Kampo medicine com-
prising ingredients that facilitate ghrelin signaling [13, 18,
19]. In gastrointestinal functional disorders, where 5-HT
is excessively released, such as disorders following cancer
chemotherapy [13] and SSRI administration [19], 5-HT
2B/2CR
stimulation causes decreased peripheral and central ghre-
lin concentrations, and RKT restores decreased peripheral
acylated ghrelin secretion to normal levels via antagonizing
these receptors. We have already demonstrated that RKT
administration improves decreased food intake in novel envi-
ronmental stress mice [14], but the underlying mechanism
remains to be sufficiently elucidated.
We hypothesized that the improvement effects of RKT
on decreased feeding behavior caused by novelty stress may
be mediated through 5-HT
2BR antagonism. To confirm this
hypothesis, abnormal ghrelin dynamics in this stress model
were clarified. In addition, to clarify the role of 5-HT
2BR in
the decreased food intake in novelty stress, the administration
of 5-HT
2BR antagonists was performed. Furthermore, we
investigated the antagonistic effects of isoliquiritigenin, a
component of RKT, on 5-HT
2BRs and its influence on food
intake.
2. Materials and Methods
2.1. Chemicals. SB215505 (5-HT
2BR antagonist) and
SB204741 (5-HT
2BR antagonist) were purchased from
Sigma-Aldrich (St. Louis, MO, USA). All chemicals were
dissolved in sterilized physiological saline before use. RKT
was used as a powdered extract which was obtained by spray
drying the hot water extract of a mixture of eight crude
drug types: sojutsu (Atractylodis lanceae rhizoma), ninjin
(Ginseng radix), hange (Pinelliae tuber), bukuryo (Hoelen),
taiso (Zizyphi fructus), chinpi (Aurantii nobilis pericarpium),
kanzo (Glycyrrhizae radix), and shokyo (Zingiberis rhizoma).
RKT and RKT components were supplied by Tsumura & Co.
(Tokyo, Japan).
2.2. Experimental Animals. Male C57BL/6J mice aged 6
weeks (Charles River Laboratories Japan, Inc., Tokyo, Japan)
were used. Before the experiment, five mice per cage were
maintained in a room with controlled temperature and
humidity under a 07:00–19:00 light cycle with free access to
food and water. For novelty stress, each mouse was trans-
ferred from group-housed cages to individual cages. Control
mice were housed in individual cages for 7 days before
the experiment was initiated. The mice in each group were
similarly handled. All experiments were performed between
09:00 and 18:00 according to the guidelines established by the
Experimental Animal Ethics Committee of Tsumura & Co.
2.3. Food Intake. All protocols were performed under a 24 h
fasting condition. Time-course evaluation of the effect of
the novelty stress on food intake in 24 h fasted mice was
undertaken 1, 2, 3, 6, and/or 24 h after exposure to the novelty
stress, and the effect was calculated as the difference between
the food weights before and after the feeding period at each
time interval.
To clarify the orexigenic action of RKT on food intake in
stressed mice, we then investigated the effects of per os (PO)
administration of RKT (500mg/kg) [14] (Figure 1(a)) or RKT
components (8-shogaol, nobiletin, tangeretin, glycyrrhizin,
glycycoumarin, and isoliquiritigenin; 4mg/kg, Figure 1(a)).
The effect of intraperitoneal (IP) administration of SB215505
(10mg/kg) or SB204741 (10mg/kg) on the novelty stress-
induced decrease in food intake was also investigated
(Figure 1(a)). The experimental doses were chosen on the
basis of a previous report [13]. RKT, RKT components,
SB215505, or SB204741 was administered immediately after
the onset of novelty stress.
2.4. Determining Plasma Levels of Ghrelin. To clarify the
alteration of peripheral ghrelin dynamics after exposure to
the novelty stress, blood was collected from mice given
ether anesthesia 0.5 and 3 h after the novelty stress under
the 24 h fasting and freely fed conditions. Blood collection
to determine plasma ghrelin levels was performed from
10:00 to 12:00. We next investigated the effect of RKT (125,
250, or 500mg/kg, PO) on plasma ghrelin concentration
levels 3 h after exposure to the novelty stress (Figure 1(b)).
RKT was orally administered 1 h before exposure to the
novelty stress, and blood was collected 3 h after the exposure.
The results of our evaluation of the postnovelty stress time
course revealed that plasma ghrelin decreased significantly
after 3 h [14]. We collected blood samples 3 h after stress to
clarify the relationship between this change in plasma ghrelin
levels and improved food intake.
The ghrelin levels were determined using commercial
ELISA kit (Mitsubishi Chemical Medience Co., Tokyo,
Japan).
2.5. Extraction of Total RNA for Reverse Transcription-
Polymerase Chain Reaction (PCR). The hypothalamus and
stomach in mice treated with distilled water or RKT
(500mg/kg) 3 h after exposure to novelty stress were rapidly
removed and immediately frozen by placing them in a tube
on dry ice. Homogenization of the isolated tissue and total
RNA extraction were performed according to the protocol
from the RNeasy Universal Tissue Kit (Qiagen, Valencia, CA,
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Figure 1: Experimental protocol. (a) Measurement of food intake. Cumulative food intake was measured at various time intervals after
exposure to the novelty stress. (b)Measurement of plasma ghrelin and tissuemRNA levels. Blood, hypothalamus, and stomach were collected
3 h after exposure to the novelty stress.
USA), after which each sample was diluted to 100 ng/𝜇L.
The diluted total RNA was incubated at 70∘C for 5min
and then cooled on ice. A TaqMan Reverse Transcription
Reagent kit (Applied Biosystems, Foster City, CA, USA) was
used according to the manufacturer’s protocol to reverse
transcribe the total RNA (1000 ng). A TaqMan Universal
PCR Master Mix (Applied Biosystems) was used to perform
quantitative PCR assays with a Prism 7900HT Sequence
Detection System (Applied Biosystems). To correct the dif-
ferences in the amount of total RNA added to each reaction,
ribosomal protein S29 (RPS29) as an endogenous control
was used to normalize mRNA expression. These differences
were expressed by the ΔCt (Ct: threshold cycle) value: ΔCt =
2(−|𝐴 − 𝐵|), where 𝐴 is the number of cycles that needed to
reach the threshold for the housekeeping gene and 𝐵 is the
number of cycles needed for the target gene. All oligonu-
cleotide primers and fluorogenic probe sets for TaqMan
real-time PCR were manufactured by Applied Biosystems
(RPS29: Mm02342448 gH, NPY: Mm00445771 m1, AgRP:
Mm00475829 g1, preproghrelin: Mm00445450 m1, ghrelin
receptor: Mm00616415 m1, orexin: Mm01964030 s1, leptin
receptor: Mm00440174 m1, and CRF: Mm01293920 s1).
2.6. Binding Assay and Cell Function Assay for 5-HT
2𝐵
R.
CHO-K1 cells stably transfected with a plasmid encoding the
human 5-HT
2BR were used to prepare membranes in mod-
ified Tris-HCl buffer. A membrane protein was incubated
with 1.2 nmol/mL [3H]LSD for 60min at 37∘C. Nonspecific
bindingwas estimated in the presence of 10𝜇mol/L serotonin.
Membranes were filtered and washed, and then, the filters
were assayed for radioactivity to determine the amount of
specifically bound [3H]LSD [20].
The antagonistic activities of compounds on human 5-
HT
2BR expressed in transfected CHO-K1 cells were deter-
mined using the HTRF detection method to measure their
effects on agonist-induced IP
1
production [21]. Cells were
suspended in 10mM HEPES buffer pH 7.4, plated in 96-well
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microplates at a density of 4 × 104 cells/well, and preincu-
bated for 5min at room temperature in the presence of the
buffer (basal control) or the test compound. Thereafter, the
reference agonist 5-HT was added at a final concentration of
30 nM. Separate assay wells did not contain 5-HT for basal
control measurements. After a 30min incubation at 37∘C, the
cells were lysed, and the fluorescence acceptor (D2-labeled
IP
1
) and donor (anti-IP
1
antibody labeled with europium
cryptate) were added. After a 60min incubation at room
temperature, the fluorescence transfer was measured at 𝜆ex =
337 nm and 𝜆em = 620 and 665 nm. The IP1 concentration
was determined by dividing the signal measured at 665 nm
by that measured at 620 nm. Results were expressed as
percent inhibition of the control response to 30 nM 5-HT. A
concentration-response curve was generated to calculate the
IC
50
values.
2.7. Statistical Analysis. Statistical analyses of mean values
of the two groups were performed using Student’s t-test or
Aspin-Welch’s t-test after the F-test. Differences in multiple
groups’ mean values were assessed by Dunnett’s analysis after
Bartlett test. Cumulative food intake data were analyzed by
repeated measures analysis of variance (ANOVA) followed
by Dunnett’s post hoc test. Data were expressed as the mean ±
standard error of themean (SEM) of each group, and𝑃 values
< 0.05 were considered to indicate statistical significance.
3. Results
3.1. Changes in Food Intake in Mice Exposed to Novelty Stress.
We investigated the effects of novelty stress on changes
in food intake (Figure 2). Two-factor repeated measures
ANOVA revealed that the effects of stress (𝐹(1, 42) = 47.93,
𝑃 < 0.001), time (𝐹(3, 42) = 1323, 𝑃 < 0.001), and stress ×
time (𝐹(3, 42) = 5.799, 𝑃 = 0.0021) were significant.
3.2. Effects of RKT on Food Intake in 24 h Fasted Mice. To
clarify the effects of RKT on food intake, RKT (500mg/kg,
PO) was administered to 24 h fasted mice. Food intake was
measured 2, 6, and 24 h after exposure to novelty stress.
RKT administration restored the decreased food intake
significantly (𝐹(1, 26) = 4.692, 𝑃 = 0.0495, Figure 3). Two-
factor repeated measures ANOVA revealed that the effects
of treatment × time (𝐹(2, 26) = 5.907, 𝑃 = 0.0077) were
significant.
3.3. Changes in Plasma Ghrelin Levels and Effects of RKT in
Mice Exposed to Novelty Stress. Wemeasured plasma ghrelin
levels to clarify whether plasma acylated ghrelin played a role
in decreasing food intake in the mice exposed to novelty
stress. Plasma acylated ghrelin and des-acyl ghrelin levels at
0.5 and 3 h under ad libitum feeding were not significantly
different between the control and novelty stress groups.
Under the 24 h fasting condition, plasma acylated ghrelin
levels in the stress group were not significantly increased
compared with those under ad libitum feeding; however, the
des-acyl ghrelin level significantly increased, while still being
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mice. ∗∗∗𝑃 < 0.001 when analyzed by two-factor repeated measures
ANOVA.
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lower than that in the control group (0.5 h; 𝑃 < 0.001, 3 h;
𝑃 < 0.001, Figure 4).
Next, we detected the effects of RKT administration
on plasma ghrelin levels under the 24 h fasted condition.
RKT administration prevented a decrease in plasma acylated
ghrelin levels comparedwith distilledwater 3 h after exposure
to novelty stress (𝑃 = 0.0074, Figure 5). The RKT-treated
mice showed a trend toward increased plasma des-acyl
ghrelin levels compared with the distilled water-treated stress
mice, but the difference was not significant.
3.4. Effects of RKT on mRNA Expression of Orexigenic Factors
in Mice Exposed to Novelty Stress. To clarify the effects of
RKT on gene expression of orexigenic factors after exposure
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Figure 5: Effect of rikkunshito on plasma ghrelin levels in mice exposed to novelty stress. Plasma ghrelin levels were determined 3 h after
onset of novelty stress. (a) Plasma acylated ghrelin level. (b) Plasma des-acyl ghrelin level. Data are expressed as the mean ± SEM of 8 mice.
∗∗∗𝑃 < 0.001 versus control group byAspin-Welch’s t-test and ##𝑃 < 0.01 versus the distilled-water-treatedmice exposed to stress byDunnett’s
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to novelty stress, we evaluated this effect on hypothalamic
and gastric mRNA expression 3 h after exposure. In the stress
group, hypothalamic NPY and AgRP mRNA showed a trend
toward decreased mRNA expression. RKT administration
(500mg/kg, PO) showed a tendency to increase NPY and
AgRPmRNA expression compared with stress, but the differ-
ence was not statistically significant (Figure 6). Preproghrelin
gene expressionwas significantly increased byRKT treatment
(𝑃 = 0.036), although this remained unchanged 3 h after
novelty stress. Levels of ghrelin receptor mRNA in the RKT-
treated mice showed an increasing trend, but the difference
was not statistically significant. Orexin mRNA expression
in the RKT-treated mice was significantly different from
that in the distilled-water-treated stress mice (𝑃 = 0.023).
There were no significant changes in leptin receptor and
CRF mRNA expression among all groups. In addition, there
were no significant changes in gastric preproghrelin mRNA
expression among all groups (control group, 1.0 ± 0.03;
novelty stress group, 1.1±0.02; stress + RKT group, 1.1±0.03
relative quantity of mRNA; data are not shown in figures and
tables).
3.5. Effects of 5-HT
2𝐵
R Antagonists on Food Intake. Cumu-
lative food intake was decreased in the group exposed to
novelty stress compared to control mice in the first 6 h after
exposure to the stress (𝐹(1, 80) = 7.647, 𝑃 = 0.0086,
Figure 7). Two-factor repeated measures ANOVA revealed
that the effects of stress× timewere not significant (𝐹(2, 80) =
1.789, 𝑃 = 0.17). Administration of a 5-HT2BR antagonist
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(SB215505; 10mg/kg, IP or SB204741; 10mg/kg, IP), signif-
icantly ameliorated the decrease in food intake (𝐹(2, 96) =
5.184, 𝑃 = 0.0092). Administration of SB215505 significantly
prevented the decrease in food intake 3 h after exposure to
novelty stress (𝑃 = 0.044), whereas SB204741 prevented the
decrease in food intake for 1 h after exposure to stress (𝑃 =
0.0015).
3.6. Effects of Herbal RKT Components on Food Intake.
We investigated the effects of six components of RKT on
decreased food intake after exposure to novelty stress. The
6 h cumulative food intake was significantly decreased in
the novelty stress-exposed mice compared with that in the
control mice (𝑃 = 0.0012, Figure 8). Isoliquiritigenin admin-
istration (4mg/kg, PO) prevented a decrease in cumulative
food intake (𝑃 = 0.045). Glycycoumarin (4mg/kg, PO)
administration showed a tendency to alleviate decreased food
intake in stressed mice, although the effect was not statis-
tically significant. The other RKT components investigated
exerted no effects on decreased food intake.
3.7. IC
50
Values for 5-HT
2𝐵
R. Table 1 shows the 5-HT
2BR-
binding inhibitory and cell function activities of isoliquiriti-
genin contained in RKT. Isoliquiritigenin showed an IC
50
for
5-HT
2BR binding of 6.3 ± 0.0 𝜇mol/L and an inhibitory cell
function activity of 2.1 ± 0.2 𝜇mol/L.
4. Discussion
In this study, we demonstrated that the novelty stress
decreased food intake and suppressed a physiological
increase in plasma acylated ghrelin levels after fasting in
mice. Oral RKT administration significantly suppressed this
novelty-induced hypophagia and decrease in acylated ghrelin
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Figure 8: Effects of rikkunshito components on 6 h food intake
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levels during fasting. Furthermore, decreased food intake
caused by the novelty stress was significantly suppressed by
5-HT
2BR antagonists and isoliquiritigenin, an ingredient of
RKT which has 5-HT
2BR antagonistic activity in vitro that
exhibits the same effect.
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Table 1: The inhibitory activity for 5-HT2B receptor.
Compound IC50 values for 5-HT2B receptor (𝜇mol/L)
Binding Cell function
OH
OH
O
Isoliquiritigenin
HO
6.3 ± 0.0 2.1 ± 0.2
Each value indicated the mean ± SEM of 3 samples.
The effects of drugs on anxiety responses in animal
models are generally evaluated by the open field test in
novelty environments [22]. In addition, novelty stress models
are one of the established methods for evaluating feeding
behavior, and novel environmental research using decreased
food intake as an index has previously been conducted [7,
23]. Using this methodology, we reported that the acute
novel environmental change caused by conversion from
group housing to individual housing significantly suppressed
feeding behavior in both young [14] and aged mice [24].
During fasting, secretion of acylated ghrelin by the
stomach was enhanced, increasing the circulating levels [25].
However, in this study, no increase was observed in the
fasting plasma levels of acylated ghrelin in mice exposed to
novelty stress. In a previous study, it was clearly demonstrated
that exogenous acylated ghrelin supplementation negated
decreased food intake in the same model as that used in
this study [14]. These results and findings suggest that the
transmission of ghrelin signals to the hypothalamic feeding
center under the fasting condition is decreased during stress
responses caused by novel environmental changes. Although
plasma des-acyl ghrelin (a metabolite of acylated ghrelin)
levels after 24 h of fasting were significantly enhanced in
mice exposed to novelty stress, the intensity of the increase
was much lower than that in the nonstress-exposed mice.
In addition, novel environmental changes did not cause
any significant changes in the expression of gastric pre-
proghrelin or ghrelin-O-acyltransferase gene (data are not
shown).Therefore, novel environmental stress suppresses the
secretion of acylated as well as des-acyl ghrelin, whereas it
does not affect the biosynthesis of acylated ghrelin in the
stomach during fasting.
NPY and AgRP gene expression in the hypothalamus
tended to decrease in the novel environmental change group
relative to that in the control group during the 3 h after
stress exposure, althoughno statistically significant difference
was observed. Ghrelin is secreted from X/A-like cells in
the gastric mucosa and acts on ghrelin receptors in vagus
nerve endings, then activating NPY/AgRP neurons in the
hypothalamic arcuate nucleus via the vagus nerve [16]. The
results of this study did not convincingly verify the attenua-
tion of ghrelin signaling caused by stress when upregulation
of hypothalamic NPY/AgRP gene expression was used as
an index for ghrelin signaling. The reason why NPY and
AgRP mRNA expression were not significantly decreased
in mice exposed to novelty stress is unknown. With regard
to NPY, there may be interference from mRNA expression
in hypothalamic tissue other than the arcuate nucleus. To
this end, the in situ hybridization technique is required for
accurate evaluation of NPY and AgRP mRNA in the arcuate
nucleus.
RKT, a Japanese Kampo medicine, is known to increase
levels of peripheral acylated ghrelin in humans [26], rodents
[13, 27], and dogs [28] as well as increase hypothalamic
acylated ghrelin in rodents [29]. RKT also enhances the
binding of ghrelin to ghrelin receptors [18, 30], resulting
in enhanced and prolonged ghrelin signaling. We have
previously reported that RKTadministration tomice exposed
to novelty stress suppresses a reduction in food intake 1 and
3 h after isolation, and the effects by RKT are abolished by
coadministration of RKT with a ghrelin receptor antagonist
[14]. The present data regarding the effect of RKT on food
intake is almost in agreement with previous findings. In
our experiment, RKT significantly reversed the decrease in
peripheral acylated ghrelin levels caused by exposure to
novelty stress. In contrast, no obvious effect of RKT was
observed on des-acyl ghrelin levels after stress. On the basis
of these results, we conclude that the increase in peripheral
acylated ghrelin level associated with RKT may be mediated
through enhanced acylated ghrelin secretion [13] in addition
to the inhibition of acylated ghrelin metabolism [27].
In this study, enhanced hypothalamic preproghrelin and
orexin mRNA expression and a tendency toward increased
ghrelin receptor mRNA expression were observed following
RKT administration. Activation of orexin neurons occurs
downstream in the ghrelin signaling pathways, and the signal
to increase appetite is transmitted to higher-order neurons
via orexin gene expression. Enhancement of orexin mRNA
by RKT may suggest ghrelin signal-enhancing effects. In
addition, RKT promoted the secretion of ghrelin in the
hypothalamus in cisplatin-induced hypophagia models [29]
and ghrelin receptor gene expression [30]. These results may
be supported by other studies indicating enhanced expression
of preproghrelin mRNA [26] and ghrelin receptor mRNA
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[30], despite differences inmodels. In addition, no significant
changes in the expression of these genes can be confirmed in
mice exposed to novelty stress. Our results were obtained 3 h
after exposure to stress, but because hypophagia was actually
observed 1 h after exposure, it may be necessary to reexamine
sampling times.
It is well known that a stress model exhibits higher
levels of central 5-HT and expression of 5-HTR, leading to
activation of the serotonergic signal [6, 24]. We previously
established the involvement of central 5-HT
2CR activation
in decreased food intake during exposure to novel envi-
ronmental stress and demonstrated that abnormalities in
ghrelin dynamics may partially contribute to this reaction
[14]. Contrary to 5-HT
2CRs, 5-HT2BRs are sparsely expressed
in discrete subregions of the central nervous system (CNS)
[31], whereas they are heavily expressed in the periphery
[32]. In a stomach, 5-HT
2BRs are distributed throughout the
gastric submucosa and smoothmuscle, and their activation is
known to result in contraction of the gastric fundus strip [33].
Although there have been several reports on the association
between stress and 5-HT in gastrointestinal organs [34, 35],
direct relationship between peripheral 5-HTR activation and
novelty stress has not been proven. In the current study,
we found that 5-HT
2BR antagonism inhibited the decrease
in food intake after novelty stress. Because there is no
information available on the 5-HT
2BR antagonists used in this
study in terms of blood-brain barrier permeability, we could
not determine whether 5-HT
2BR antagonism was effective
in the CNS or the peripheral in the present study. Further
investigation is required to determine the 5-HT
2BR activating
site under stress.
5-HT
2BR activation by peripheral administration of a
5-HT
2BR agonist has been shown to cause a decrease in
food intake [12] and inhibition of ghrelin secretion [13]. We
also found that peripheral administration of BW723C86, a
5-HT
2BR agonist, decreased plasma acylated and des-acyl
ghrelin levels in normal rats (see SupplementalMaterial avail-
able online at http://dx.doi.org/10.1155/2013/792940). These
findings suggest that 5-HT
2BR activation is associated with
abnormal ghrelin dynamics.
In the present study, the effects of certain RKT com-
ponents on food intake in stress models were examined.
Administration of isoliquiritigenin (4mg/kg) significantly
improves novelty stress-induced hypophagia. We also found
that isoliquiritigenin inhibited binding between 5-HT and
5-HT
2BR and confirmed that it has an obvious antagonistic
effect on 5-HT
2BR using a cell function assay. We previously
reported that glycycoumarin, which has an antagonistic effect
on 5-HT
2BR [13], suppressed decreased food intake 3 h after
the application of stress [14]. It seems likely that glycy-
coumarin may inhibit the decrease in food intake after expo-
sure to novelty stress via 5-HT
2BR antagonism. Therefore,
multiple RKT ingredients having an antagonistic effect on 5-
HT
2BR act and are considered to be responsible for its effects.
5. Conclusion
In conclusion, RKT has an ameliorating effect on decreased
food intake caused by novel environmental changes. This
effect appears to be mediated through improvement of
abnormal ghrelin dynamics by 5-HT
2BR antagonism.
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Gastrointestinal disturbances, such as nausea and vomiting, are considered amongst the main adverse effects associated with oral
anticancer drugs due to their fast release in the gastrointestinal tract (GIT). Sustained release formulations with proper release
profiles can overcome some side effects of conventional formulations. The current study was designed to prepare sustained release
tablets of Capecitabine, which is approved by the Food andDrugAdministration (FDA) for the treatment of advanced breast cancer,
using hydroxypropyl methylcellulose (HPMC), carbomer934P, sodium alginate, and sodium bicarbonate. Tablets were prepared
using thewet granulationmethod and characterized such that floating lag time, total floating time, hardness, friability, drug content,
weight uniformity, and in vitro drug release were investigated. The sustained release tablets showed good hardness and passed the
friability test. The tablets’ floating lag time was determined to be 30–200 seconds, and it floated more than 24 hours and released
the drug for 24 hours. Then, the stability test was done and compared with the initial samples. In conclusion, by adjusting the right
ratios of the excipients including release-retarding gel-forming polymers like HPMCK4M,Na alginate, carbomer934P, and sodium
bicarbonate, sustained release Capecitabine floating tablet was formulated.
1. Introduction
After cardiovascular disease, cancer is the second reason for
death. Prostate, lung, colon, and breast cancers are the most
common forms of cancer. The present treatments for can-
cer include surgery, chemotherapy, hormone therapy, gene
therapy, and radiation therapy. Currently, chemotherapeutic
drugs are the most common type of cancer treatment. How-
ever, the administration of high doses of these drugs leads
to some adverse toxic effects. As some reports indicated,
many side effects, such as systemic side effects, diarrhea, and
gastrointestinal problems will appear in anticancer therapy
[1–5].
Many drugs, such as Anthracyclines, Taxanes (Doc-
etaxel, Paclitaxel), Gemcitabine, Vinorelbine, Carboplatin,
Trastuzumab, Lapatinib, Cyclophosphamide, Methotrexate,
Adriamycin, Epirubicin, Mitoxantrone, Bevacizumab, and
Capecitabine, are used in breast cancer.The use of these drugs
is strongly recommended to make sure that the side effects
and high dosage of these drugs are balanced [4, 6–8].
Capecitabine, 5󸀠-deoxy-5-fluoro-N-((pentyloxy)carbonyl)-
cytidine, is a fluoropyrimidine carbamate which has an anti-
neoplastic activity. This chemical is a prodrug of 5󸀠-deoxy-5-
fluorouridine (5󸀠-DFUR), which is enzymatically converted
in vivo to 5-fluorouracil (5-FU).The commercial brand name
is Xeloda, which has a biconvex face and a coated film (such
as a light peach-colored film for 150mg Capecitabine and
peach-colored film for 500mgCapecitabine). But both tablets
have the same inactive excipients: hydroxypropyl methylcel-
lulose, Croscarmellose sodium, magnesium stearate, micro-
crystalline cellulose, anhydrous lactose, and purified water.
Also, the light peach- or peach-colored film contains talc,
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Table 1: Different formulations of tablets with different concentrations (%).
HPMC S.A Car S.B Lac PEG Mg.St Cap Total
F1 20 20 1.6 13.3 35 6.6 3.3 150 300
F2 20 20 3.3 13.3 33.3 6.6 3.3 150 300
F3 20 20 4.6 13.3 32 6.6 3.3 150 300
F4 16.6 16.6 3.3 13.3 40 6.6 3.3 150 300
F5 16.6 20 3.3 13.3 36.6 6.6 3.3 150 300
F6 16.6 23.3 3.3 13.3 33.3 6.6 3.3 150 300
F7 20 16.6 3.3 13.3 36.6 6.6 3.3 150 300
F8 20 20 3.3 13.3 33.3 6.6 3.3 150 300
F9 20 23.3 3.3 13.3 30 6.6 3.3 150 300
F10 23.3 16.6 3.3 13.3 33.3 6.6 3.3 150 300
F11 23.3 20 3.3 13.3 30 6.6 3.3 150 300
F12 23.3 23.3 3.3 13.3 26.6 6.6 3.3 150 300
hydroxypropyl methylcellulose, titanium dioxide, and red
and yellow iron oxides [9].
Important problems of Capecitabine as to the cur-
rent clinical treatment are a short half-life and its rapid
metabolism in the liver.Therefore, the administration of high
doses of Capecitabine leads to some undesirable side effects
[10]. All these problems can be resolved using sustained
release. Based on previous research, since the advantages of
these systems are to achieve the therapeutic concentration,
the desired drug release rate prolonged drug release and
reduction of the repeating dosage. Many of these problems
can be resolved if sustained release is done [10, 11].
Sustained release (SR) tablets of anticancer drugs could
not only provide an optimum plasma concentration with
less frequent administration but also help decrease the side
effects of conventional dosage forms, such as GIT problems
[12].This could increase the safe administration and improve
patient compliance. Nowadays, some pharmaceutical prod-
ucts are considered as controlled-release, which can also be an
effective way to deliver different types of drugs into the tissues
or cells, such as diltiazem hydrochloride, chlorpheniramine
maleate, ciprofloxacin, theophylline, famotidine, and capto-
pril [5, 13–16].
There are several advantages to making sustained release
antineoplastic drugs like Capecitabine. These drugs show
fewer side effects, have longer half-lives, require less frequent
dosages, and improve efficacy. Thus, there would be better
patient compliance and less variation in plasma/blood levels
[17]. The gastroretentive drug delivery system is formulated
to keep the tablet in the stomach for several hours and can
improve the drug’s solubility and bioavailability and reduce
drug waste [5, 18]. This study aimed to prepare the floating
dosage formof anticancer drugs, to characterize the sustained
release tablet in terms of total floating time, dissolution,
friability, hardness, drug content, and weight uniformity,
to compare the prepared formulation with the commercial
tablet in terms of drug release, and to evaluate the stability of
the formulation by accelerating and long term condition
according to the International Conference onHarmonization
(ICH) procedure.
2. Materials and Methods
2.1. Materials. Capecitabine was a kind gift from Osvah
Pharmaceutical Company (Tehran, Iran). The 5 FU was
provided from sigma Aldrich (KL, Malaysia). HPMC K4M
was supplied by Sigma Chemicals. Sodium alginate and
sodium bicarbonate were purchased from R&M chemicals
(KL, Malaysia),carbomer934p was purchased from Noveon,
polyethylene glycol 3500 from Merck, magnesium stearate
from Mallinckrodt, and lactose from HMbG chemicals
(United State of America). All reagents were of analytical or
pharmaceutical grade.
2.2. Methods
2.2.1. Preparation of Sustained Release Capecitabine. Sus-
tained release tablets were formulated with different types
and ratios of polymers using the wet granulation method,
and then tablets were compressed directly by a single punch
machine. Capecitabine was mixed with carbomer934p as a
control release agent, with HPMC K4M as a binder, sodium
alginate for gel forming, and sodium bicarbonate to extend
floating time. All components were mixed for 10min, and
then Isopropyl alcohol was added dropwise to make a good
wet mass of granules. After remixing for 5min, the granules
were passed through a 400𝜇m mesh sieve. Wet granules
were put in a 40∘C oven for 40min to become dry, and
then PEG 3500 and magnesium stearate were added to the
granules as lubricating agents. Eventually, 300mg of the
mixture was weighted and compressed on an 8mm flat face
by a single punchmachine. In this study, 12 formulationswere
designedwith 150mg of Capecitabine, and the different ratios
of polymers are as shown in Table 1.
2.2.2. Kinetic Modeling of Release Profiles. The dissolution
results of all formulations in 0.1 N HCl were specified to
Higuchi, Korsmeyer-Peppas, Hixson-Crowell, Weibull, and
first order and zero order kinetic models. The model with
themaximumcorrelation coefficient was considered to be the
best model [19–24].
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2.2.3. Determination of Floating Lag Time and Total Floating
Time. Thefloating lag time (FLT) is the time taken for a tablet
to rise on medium surface, and total floating time (TFT) is
the floating duration that a tablet remained on surface. To
determine the floating lag time, tablets (𝑛 = 4) were put on
100mL of 0.1 N HCL in a beaker, and the time is required for
a tablet to rise on surface was measured. Then, the duration
of each formulation that remained on the surface was deter-
mined as total floating [15, 25].
2.2.4. Tablet Hardness. To evaluate tablet hardness, 10 tablets
of each formulation were tested for diametrical crushing
strength using a hardness tester (Dr. schleuniger, 6D-Tablet
Tester).
2.2.5. Tablet Friability. The friability of the SR tablets (𝑛 = 10)
was tested by a friabilator (ERWEKA, TAR 10), at a speed of
100 rpm for 5 minutes.
Hardness and friability values were determined and
reported as mean ± SD.
2.2.6. Drug Content of the Tablets. To evaluate the drug con-
tent through a uniformity test, 10 tablets of each formulation
were crushed and suspended in 0.1 N HCL to remove the
Capecitabine from the tablets. After 24 hours, media were fil-
trated and measured by a UV spectrophotometer (Shimadzu
1601) at 214 nm [26, 27].
2.2.7. Tablet Weight Uniformity. An electronic balance (Met-
tler Toledo, 3-MS-S/MS-L, Switzerland) was used to accu-
rately weigh ten tablets which were randomly selected. The
results are expressed as mean values ± SD [26, 27].
2.2.8. In Vitro Release Study. A dissolution test was per-
formed for 24 hours using the ERWEKA DT70 dissolution
machine according to American pharmacopeia [25]. Each
vessel contained 1000mL of 0.1 N HCL; the paddle apparatus
with 50 rpm speed was also used, while the temperature was
kept stable at 37∘C. Every two hours till 24 hours, 10mL of
mediawaswithdrawn andmeasured byUV spectrophotome-
ter at 214 nm (Shimadzu 1601). Furthermore, 10mL of 0.1 N
HCL was replaced to keep the volume stable.
Two formulations (commercial (Xeloda) and prepared
tablet) were compared in terms of drug release.
At the end, all results were analyzed using Microsoft
Excel. The dissolution test was repeated 4 times for each
formulation.
2.2.9. Preparation of Standard Curve. The standard curve
was constructed using six different concentrations of Cape-
citabine, ranging from 100 to 12.5mg. To make a standard
curve, 5mg of Capecitabine was dissolved in 50mL of 0.1 N
HCL. Then, 3mL of each dilution was measured by UV
spectrophotometer (Shimadzu 1601).
2.2.10. Stability Study Test. To study the quality of the finished
product under a variety of conditions (time, humidity, and
temperature) and to evaluate the formulation, stability studies
were prepared for 6 and 12 months according to the ICH
Table 2: Storage conditions for tablet stability test.
Type of study Condition Time
Accelerated 40∘C ± 2∘C, 75% RH ± 5% RH 6 months
Long term 25∘C±2∘C, 60% RH ± 5% RH 12 months
Table 3: Drug release and floating profiles of twelve formulations.
Formulation Release % Floating lagtime (s)
Total floating
time (h)
F1 100 30 20
F2 83.665 70 24
F3 76.3 81 24
F4 100 35 20
F5 90.305 45 24
F6 84.711 60 24
F7 98.286 60 24
F8 83.665 70 24
F9 78.82 85 24
F10 86.666 60 24
F11 80.54 80 24
F12 75.226 200 0.5
s: second; hr: hour.
(International Conference on Harmonization) procedures.
After storage, all samples were analyzed for their physical
characterizations.
Tablets (𝑛 = 4) were used for the stability studies accord-
ing to ICH long term and accelerated procedure. All tablets
were stored in standard condition in WTB binder APT line
(Table 2).
All the tablets were packed in polyethylene bags.The bags
were clamped using clamping tape and double-packed by
putting in cardboardwith a plywood lid and the lidwas sealed
[28–31].
2.2.11. Statistical Analysis. The results were evaluated by one-
way analysis of variance (ANOVA) using Duncan’s multiple
comparison test. Differences were considered significant at 𝑃
value equal to or less than 0.05 [32, 33].
3. Results and Discussion
3.1. Floating Profile. The sustained release Capecitabine float-
ing tablets were developed using release-retarding gel-
forming polymers HPMC K4M, Na alginate, and car-
bomer934P, accompanied by sodium bicarbonate as a gas-
forming agent and lactose as filler.
Table 3 shows the results of the floating and releasing
times of 12 prepared formulations over 24 hours.
The investigated gastric floating systems employed
sodium bicarbonate (NaHCO
3
) as a gas-forming agent,
which is trapped in a hydrogel matrix (HPMC K4M and Na
alginate). The in vitro study revealed that most formulations
are able to keep the drug buoyant formore than 24 h (Table 3).
This suggests that the gel layers, formed by the investigated
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polymers, enabled efficient entrapment of the generated CO
2
bubbles.
The floating lag time for most formulations was below
90 seconds, regardless of the content of polymers used
(Table 3), indicating significance of the polymers’ concentra-
tions (Table 1). The interaction between sodium bicarbonate
(NaHCO
3
) as a gas-generating agent and the dissolution
medium (0.1mol L−1 HCl, pH 1.2) generated and entrapped
CO
2
inside the jellified polymeric matrices, inducing the
tablet to float. A decrease in tablet-specific gravity causes the
tablet to float on extended residence time in the stomach,
improving absorption.
As the amount of carbomer934P increased, TFT
decreased—this could be due to the high affinity of carbomer
towards water, which promotes water penetration into
polymeric matrices, leading to increased density. As the
amount of HPMC K4M increased, the total floating time
increased—this is because of the increased gel strength of the
matrices, which prevents the escape of involved CO
2
from
the matrices, leading to decreased density. As the amount of
SA increased, TFT decreased—this is because of the poor
gelling strength of SA compared to HPMC K4M that was
previously reported [34, 35].
3.2. Drug Release Profiles. Depending on the type and con-
centration of polymers, variable drug release profiles were
successfully tailored.
The dissolution profile of the best formulation (formula-
tion F7) according to standard curve and R2 (Figure 2) was
choose and is shown in Figure 1, with appropriate release
rate near zero order release kinetic. Drug release involves a
combination of swelling, diffusion, and erosion of matrices.
This might be due to the water solubility of Capecitabine as
well as different characteristics of polymers.
The influence of carbomer934P, HPMC K4M, and Na
alginate on the release of capecitabine from the floating
tablets in 0.1 N HCl (pH 1.2) at 37 ± 0.5∘C was shown in Fig-
ures 3, 4, 5, and 6. It is clear that all formulations succeeded in
controlling the rate of drug release. However, the drug release
rate was dependent on the type and concentration of the col-
laborated polymers. A higher concentration of HPMC K4M
would promote the formation of highly viscous gels upon
contact with aqueous fluids. This would promote retardation
of the drug release rates. Siepmann and Peppas [36] suggested
that drug release from HPMC matrices is sequentially gov-
erned as follows: at the initial time, when the tablet contacts
the media, water can penetrate into the polymeric complex,
and due to water absorption, HPMC will swell and increase
the dimensions of the complex. Then, drug will dissolve
and diffuse out due to the concentration of the polymers.
The results of 𝑡
50
(time required for 50% drug release)
showed wide variations. From the results of multiple regres-
sion analysis, it was found that the dependent variable,
𝑡
50
, is strongly dependent on the independent variables
(carbomer934P, HPMC, and Na alginate). As the amount of
HPMCK4M and carbomer934P increased, 𝑡
50
decreased and
floating lag time increased; again, this may be due to the high
affinity of HPMC and carbomer934P towards water, which
promotes water penetration into polymeric matrices, leading
0
0.5
1
1.5
2
2.5
0 20 40 60 80 100
Ab
so
rb
an
ce
Concentration (mg/mL)
Standard curve
y = 0.0251x
R
2
= 0.9998
Figure 1: Calibration curve of Capecitabine in HCL 0.1 N.
0
20
40
80
60
100
120
0 5 10 15 20 25 30
C
on
ce
nt
ra
tio
n 
(%
)
Time (hour)
F1
F2
F3
F4
F5
F6
F7
F8
F9
F10
F11
F12
ACC
Long
Figure 2: In vitro release profiles of various Capecitabine floating
formulations in 0.1 N HCl (pH 1.2) at 37 ± 0.5∘C (𝑛 = 4).
to solubility of Capecitabine. As the amount of Na alginate
increased, 𝑡
50
decreased probably because of the poor water
affinity of Na alginate compared to HPMC K4M and car-
bomer934P.
As this and previous studies [5, 37, 38] have shown that,
upon contact with aqueous media, polymers would produce
strong barriers that would effectively reduce the burst release.
Taking into consideration the aim of the research of achieving
a compromise between excellent floating behavior (short
floating lag time and long total floating time) and sustained
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Table 4: Mathematical release modeling of sustained release capecitabine floating tablets.
Formulations code Zero order 𝑅2 First order 𝑅2 Higuchi 𝑅2 Hixson-Crowell 𝑅2 Korsmeyer-Peppas
F1 0.964 0.818 0.983 0.908 0.482
F2 0.996 0.972 0.977 0.990 0.576
F3 0.992 0.959 0.970 0.980 1.606
F4 0.871 0.974 0.962 0.940 0.413
F5 0.989 0.968 0.988 0.993 0.558
F6 0.996 0.926 0.954 0.963 0.564
F7 0.989 0.851 0.988 0.960 0.596
F8 0.996 0.972 0.977 0.990 0.575
F9 0.997 0.943 0.955 0.969 0.625
F10 0.993 0.936 0.980 0.973 0.590
F11 0.998 0.951 0.962 0.976 0.621
F12 0.992 0.954 0.967 0.976 1.644
Acc 0.922 0.857 0.986 0.955 0.464
Long 0.955 0.894 0.997 0.918 0.464
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Figure 3: The influence of carbomer934P on the release of
Capecitabine from the SR tablets in 0.1 N HCl (pH 1.2) at 37 ± 0.5∘C
(𝑛 = 4).
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Figure 4: The influence of HPMC K4M in F4, F7, and F10 on the
release of Capecitabine from the SR tablets in 0.1 N HCl (pH 1.2) at
37 ± 0.5∘C (𝑛 = 4).
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Figure 5: The influence of Na alginate in F4, F5, and F6 on the
release of Capecitabine from the SR tablets in 0.1 N HCl (pH 1.2)
at 37 ± 0.5∘C (𝑛 = 4).
drug release characteristics, formula F7 was chosen for
further studies.
An immediate release rate was achieved following the
dissolution of a commercial brand of Capecitabine 150mg
tablets in 0.1 N HCl. Indeed, 100% of the drug was released
within 40min (Figure 7). There was a significant difference
between immediate release and sustained release (𝑃 < 0.05).
The rate of immediate release significantly increased and
most of the drug was released within the first 30 minutes,
but in sustained release, the drug release increased gradually
during 24 hours (Figure 7).
3.3. Kinetic Results. To establish the mechanism of drug
release, all data from the dissolution studies of floating tablets
were obtained and fitted in kinetic models (Table 4) [19,
23, 24, 39]. The correlation coefficient (𝑅2) was used as an
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Figure 6:The influence ofNa alginate in F7, F8, andF9 on the release
of Capecitabine from the SR tablets in 0.1 N HCl (pH 1.2) at 37 ±
0.5∘C (𝑛 = 4).
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Figure 7: Release profiles of a commercial brand of Capecitabine
and F7 (𝑛 = 4).
indicator for best fitting, in which all formulation regression
values were between (𝑅2) = 0.998 to 0.871 zero order. By
comparing the regression values of different models, the zero
order model was found to be the best model for optimum
formulation (F7) (Table 4). According to the results, it could
be predicted that the drug releasemodel of the prepared tablet
was of the diffusion type.
3.4. Physical Properties. Previous studies have reported that
tablet hardness not only had a slight effect on drug release
profiles but was also a determining factor with regards to
buoyancy of the tablets. Increasing the hardness would pos-
sibly lead to prolongation of the floating lag time by affecting
the rate of the tablet penetration by the dissolution medium.
Also, the percentage friability for all formulae was less than
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Figure 8: Comparison of the release profiles of F7 and stored tablets
(𝑛 = 4).
Table 5: Comparison of physical properties of all formulations.
Hardness
(N)
Friability
(%)
Drug content
(%)
Weight
uniformity (mg)
F1 57 0.35 99.33 ± 0.81 299 ± 0.89
F2 76 0.26 98.61 ± 1.13 300 ± 0.75
F3 81 0.22 99.45 ± 0.19 301 ± 0.82
F4 55 0.35 99.83 ± 0.88 298 ± 1.04
F5 62 0.29 98.17 ± 1.05 299 ± 0.79
F6 68 0.25 99.05 ± 0.71 299 ± 0.9
F7 69 0.31 99.79 ± 0.48 299 ± 0.18
F8 76 0.26 98.61 ± 1.13 298 ± 0.62
F9 80 0.21 99.86 ± 0.36 300 ± 0.25
F10 95 0.19 99.25 ± 0.51 298 ± 0.72
F11 104 0.11 98.48 ± 0.19 300 ± 0.43
F12 112 0.103 99.01 ± 0.47 299 ± 1.09
1%, indicating goodmechanical resistance.Thephysicochem-
ical properties of the tablets are as summarized in Table 6.
All tablet formulae showed (Table 5) acceptable physico-
chemical properties and complied with the pharmacopoeia
specifications [25, 26] for weight variation, drug content and
friability.Theweight of the tablets ranged from 298 to 301mg.
Drug uniformity results were found to be good among
different formulations, where the percentage of drug content
ranged from 98.06% to 99.86%.
3.5. Drug Release and Physical Profile in Stability Condition.
The optimum formulation (F7) was packed according the
standard procedures, and was analyzed by dissolution and
physical characterization procedures after storage (Tables 2
and 6 and Figure 8).
The drug release of the stored samples was slightly
affected by the different storage conditions, indicating that
either heat or humidity affected the permeability of the poly-
meric matrix.
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Table 6: Drug release and physical properties of stored tablet.
Formulation Release % Floating lagtime
Total floating
time
Hardness
(N)
Friability
(%)
Drug content
(%)
Weight
uniformity
(mg)
ACC 99.216 80 s 20 h 57 0.30 98.06 ± 0.61 298 ± 0.41
Long 100 65 s 23 h 65 0.33 99.37 ± 0.82 299 ± 0.16
Accelerated test (which carried out at 40∘C and 75%
humidity) affected the floating ability of tablets by slight
decrease in floating time.
3.6. Statistical Analysis Results. Before and after conducting
the stability studies, statistical analyses of the results for
storage months were carried out by one-way ANOVA. No
significant difference (𝑃 value > 0.05) was observed in the
drug release.
F7 stability test after 6 months: there was no significant
effect of accelerated term on F7 stability conditions at the 𝑃 <
0.05 level for the three conditions (𝐹(1, 26) = 1.108138, 𝑃 =
0.302173, and Fcrit = 4.225201).
F7 stability test after 12 months: there was no significant
effect in release rate and stability of F7 after 12 months at the
𝑃 < 0.05 level for the three conditions (𝐹(1, 26) = 0.285179,
𝑃 = 0.597864, and Fcrit = 4.225201).
F7 stability test in 6 and 12 months: there was no signifi-
cant effect of 6 months and 12 months on stability condition
at the 𝑃 < 0.05 level for the three conditions (𝐹(1, 26) =
0.260494, 𝑃 = 0.614087, and Fcrit = 4.225201).
4. Conclusion
The purpose of this study was to prepare a sustained release
tablet of Capecitabine with a 24-hour gradual release with
concurrent floating. In doing so, various polymers, such as
HPMCK4M, sodium alginate, and sodium bicarbonate, were
tested. Also, characterization tests such as floating lag time,
total floating time, release measurements, hardness, friability,
content uniformity, and weight uniformity were performed.
Comparisons of all release studies showed that the drug
release depended on the ratio of two polymers—HPMC
K4M,whichwas used as a binder; and sodiumalginate, which
created gel-forming capabilities in the tablet.
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Nutritional or dietary factors have drawn attention due to their potential as an effective chemopreventive agent, which is considered
a more rational strategy in cancer treatment. This study was designed to evaluate the effect of IP
6
extracted from rice bran on
azoxymethane- (AOM-) induced colorectal cancer (CRC) in rats. Initially, male Sprague Dawley rats were divided into 5 groups,
with 6 rats in each group. The rats received two intraperitoneal (i.p.) injections of AOM in saline (15mg/kg body weight) over a 2-
week period to induce CRC. IP
6
was given in three concentrations, 0.2% (w/v), 0.5% (w/v), and 1.0% (w/v), via drinking water
for 16 weeks. The deregulation of the Wnt/𝛽-catenin signaling pathway and the expression of cyclooxygenase (COX)-2 have
been implicated in colorectal tumorigenesis. 𝛽-Catenin and COX-2 expressions were analysed using the quantitative RT-PCR and
Western blotting. Herein, we reported that the administration of IP
6
markedly suppressed the incidence of tumors when compared
to the control. Interestingly, the administration of IP
6
had also markedly decreased 𝛽-catenin and COX-2 in colon tumors. Thus,
the downregulation of 𝛽-catenin and COX-2 could play a role in inhibiting the CRC development induced by IP
6
and thereby act
as a potent anticancer agent.
1. Introduction
Inositol hexaphosphate (IP
6
) is a dietary component that
constitutes approximately 1 to 5% of the weight of most
cereals, nuts, oil seeds, legumes, and grains [1, 2]. In partic-
ular, approximately 9.5 to 14.5% of the weight of rice bran is
composed of IP
6
. Phytic acid or IP
6
is a polyphosphorylated
carbohydrate with six phosphate groups, each attached to
a carbon atom [3]. Myoinositol is the parent compound of
IP
6
. The phosphate grouping in positions 1, 2, and 3 (axial-
equatorial-axial) is unique for IP
6
and suggests tremendous
chelating potential [3], thereby it has a potential role as anti-
cancer agent. According to previous research, IP
6
exhibits a
variety of chemopreventive properties, including antioxidant
and anticancer properties [4, 5]. Matejuk and Shamsuddin
suggested that IP
6
acts as a protective agent in cancer develop-
ment [6].
Preclinical studies have been conducted to evaluate the
potential anticancer properties and tolerability of IP
6
in
cancer treatment [6]. However, because these studies have
not evaluated the anticancer potential and toxicity effects of
IP
6
extracted from rice bran, its specific mechanism of action
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as an anticancer agent remains unexplored. Furthermore,
the antiproliferative activity of IP
6
is most likely mediated
through the coordinated activity of a number of molecules,
although the exact signaling network involved in eliciting this
response is unclear. Therefore, our study aims to evaluate the
anticancer potential of IP
6
extracted from rice bran and to
determine its mechanism of actions.
Furthermore, Singh et al. [7] have previously analyzed
the anticancer efficacy of oral IP
6
against human prostate
carcinoma xenograft in vivo, in which IP
6
suppressed the
tumor growthwithout any toxicity. IP
6
also has been found to
be effective in animal tumorigenesis models of other cancer
types without any toxicity [8]. In addition, our earlier study
has reported that no toxic effect has been found in liver and
kidney after the administration of IP
6
to treat colorectal
cancer (CRC) in AOM-induced rats [9].
CRC is ranked as the third most prevalent cancer and
the second leading cause of disease-related deaths in the US
[10]. CRC results in, when normal glandular epithelial cells
accumulate acquired genetic and epigenetic changes that
transform the cells into invasive adenocarcinomas. In other
words, when normal epithelium transforms into an adenoma,
it can eventually invade nearby colon tissue and metastasizes
[11]. Carcinogenesismay be targeted atmultiple points during
its sequence to prevent the development of adenocarcinoma.
Potential preventive agents that help suppress colon carcino-
genesis can lead to chemoprevention of the disease [12]. To
date, many chemopreventive agents from natural products
and their phytochemical constituents are known to interact
with diverse molecular targets during carcinogenesis [13]. A
broad range of nutraceutical compounds possess remarkable
therapeutic properties; therefore, we aimed to examine the
development of an alternative compound from Malaysian
sources, particularly rice bran. Rice bran which is composed
of pericarp, seed coat, nucellus, aleurone layers, and germ is
a byproduct of rice milling in the production of white rice.
Abnormal activation of the Wnt/𝛽-catenin pathway has
been implicated in human CRC [14]. This activation occurs
due to the overexpression of theWnt ligand and/ormutations
in the downstream molecules of the Wnt signaling cascade,
such as the APC and 𝛽-catenin genes [15]. Therefore, the
Wnt/𝛽-catenin pathway is considered a therapeutic target for
the prevention and treatment of CRC.
Spychalski et al. [14] reported that, in addition to
excessive 𝛽-catenin, overexpression of COX-2 and increased
prostaglandin (PG) production from free arachidonic acid
also contribute to CRC development. Overexpression of cy-
clooxygenase-2 (COX-2) has been reported in approximately
90% of colon tumors and premalignant colorectal adenomas
[16, 17]. COX-2 is an inducible prostaglandin G/H synthase
and was identified to have a vital function in prostaglandin
(PG) synthesis. In addition to the COX-2/PGE2 signaling
pathway, a lot of natural products and their active phyto-
chemicals have been proven to have chemopreventive poten-
tial that can modulate various signal transduction pathways
underlying colon carcinogenesis [13]. This was proven by
Reddy et al. [18] who have shown that wheat bran fractions
play a role in reducing iNOS and COX-2 expressions in CRC.
Moreover, reduction in transcriptional activity of COX-2 has
been shown after administration of anthocyanin-rich extracts
of bilberry and grape in AOM-induced rat [19]. Bakhle [20]
has previously reported that the COX-2 protein is normally
absent in cells. To the best of our knowledge, the effects of
IP
6
in altering the expression of 𝛽-catenin and COX-2 have
not been described earlier. Hence, we intend to investigate the
effects of IP
6
for the first time on these two pathways during
colon tumorigenesis.
2. Materials and Methods
2.1. Chemicals. Hexane and hydrochloric acid (HCl) were
purchased from Merck (Darmstadt, Germany). Iron chlo-
ride (FeCl
3
), azoxymethane, and sodium hydroxide (NaOH)
were purchased from Sigma (St. Louis, MO, USA). Western
blotting reagents were purchased from Bio-RAD (CA, USA).
Dimethylformamide (DMF) was purchased from Fermentas
(Lithuania, EU). Other chemicals used in this study were of
the highest commercial grade.
2.2. Preparation of IP
6
. Freshly milled raw rice bran samples
from mixed local varieties (MR 84 and MR 219) were kindly
supplied by the BERNAS Milling Plant (Selangor, Malaysia).
The branwasmicrowaved immediately and stabilized accord-
ing to the method used by Ramezanzadeh et al. [21]. Then,
2mL of hexane was added to every 0.5 g of rice bran and
soaked overnight to produce defatted rice bran [22]. The
rice bran was then filtered and dried by evaporation using
a vacuum pump apparatus. After that, IP
6
was extracted as
follows: using a slight modification to previously described
methods [23]. The defatted rice bran was combined with
hydrochloric acid (0.5MHCl) and continuously shaken in an
orbital mixer for 2 hours at room temperature. The mixture
was then centrifuged at 17,300 g for 30 minutes at 15∘C, and
the supernatant containing IP
6
was collected. To neutralize
the sample, FeCl
3
was added to the IP
6
, and the mixture was
placed in a boiling water bath to allow complete precipitation
of the ferric phytate complexes. Ferric phytate was then
heated with NaOH and centrifuged to obtain ferum (III),
hydroxide (pellet), and sodium phytate (supernatant) [24].
Finally, the supernatant was collected and freeze dried. We
successfully extracted and obtained the pure IP
6
from rice
bran in our laboratory. The determination of IP
6
was done
by HPLC analysis [23].
2.3. Animals. Male Sprague Dawley rats weighing approx-
imately 50 g were acclimatized for seven days and fed on
normal rat chow, according to the AIN 76-A guidelines, and
tap water was provided ad libitum. Rats were housed in
individual cages, which were fully ventilated and maintained
at room temperature on a 12-hour light-dark cycle. All of
the experimental protocols involving animals were approved
by the Animal Care and Use Committee of the Faculty of
Medicine and Health Sciences, Universiti Putra Malaysia
(UPM), Serdang, Selangor, Malaysia.
2.4. Experimental Design. Rats were acclimatized for seven
days and randomized into experimental and control
BioMed Research International 3
groups. The animals were injected intraperitoneally with
azoxymethane (AOM), a specific carcinogen that was diluted
in saline, once per week (15mg/kg body weight), over a
2-week period to induce colonic tumors [9, 25]. Rats were
divided into 5 groups (𝑛 = 6). Group 1 was the control
group. Groups 2–5 received intraperitoneal (i.p.) injections
of AOM once per week, for two consecutive weeks at a dose
of 15mg/kg body weight, as mentioned above. Starting one
week after the second dosing with AOM, groups 3–5 received
various concentrations of IP
6
[0.2% (w/v), 0.5% (w/v), and
1.0% (w/v)] in their drinking water for a period of 16 weeks.
These concentrations were achievable physiologically in rat
tumor models considering the doses used which give rise
to inhibition of tumor incidence [9, 26]. All of the rats were
carefully observed on a daily basis, and their body weights
were recorded weekly. At the end of the experiment, all of
the rats were euthanized by cervical decapitation, and the
whole colon tissues were collected, weighed, and processed
immediately for further analysis.
2.5. Detection of Aberrant Crypt Foci (ACF) and Tumor
Assessment. The colons were resected and flushed with 10%
neutralized formalin to remove residual bowel contents, cut
open longitudinally and submerged overnight in 10% (v/v)
neutralized formalin. The tissue samples were dehydrated
in an ascending series of alcohol dehydration, cleared with
xylene, andwax impregnatedwith paraffinwax for 14 hours in
an automatic tissue processor machine. Sections (3 𝜇M) were
stained with hematoxylin and eosin (H & E).
ACF were identified using a published set of criteria
which distinguishes these lesions from normal crypts [25].
Tumor assessment parameters have been previously de-
scribed by Bird [25]. Briefly, tumor incidence is the percent-
age of total animals with tumors as follows:
tumor incidence
=
total animals with adenoma and/or adenocarcinoma
total animals
.
(1)
2.6. Analysis of 𝛽-Catenin and COX-2 Expression by Real-
Time PCR. The extraction of total RNA from fresh whole
colon tumor tissue was performed using TRI Reagent (Sigma,
MO, USA). Tissue disruption and homogenization were
performed such that the colon tumor tissue was weighed
out (20–30mg), immediately placed in liquid nitrogen, and
homogenized using a tissue grinder. The tissue powder and
liquid nitrogen were decanted into an RNase-free, 2mL
microcentrifuge tube, and the liquid nitrogen was allowed
to evaporate. Then, the tissue samples were homogenized in
1mL of TRI Reagent per 50–100mg of tissue for 10 minutes.
RNA extraction was then performed according to the manu-
facturer’s instructions, and 1 𝜇g of the total RNA sample was
reverse transcribed using theGeneAmpGoldRNAPCRCore
Kit (Applied Biosystems, California, USA) in a final reaction
volume of 20 𝜇L, according to the manufacturer’s protocol.
The reverse transcription reaction was carried out at 42∘C
for 30 minutes in an authorized thermal cycler (Eppendorf,
NY, USA), followed by a 10-minute step at 99∘C to denature
the enzyme; then, it was cooled to 4∘C. This cDNA was
then used as a template for amplification in real-time PCR
reactions. Quantitative real-time PCR was performed in a
reaction volume of 20 𝜇L, according to the manufacturer’s
instructions for the KAPA SYBR Green FAST qPCR kits
(Kapa Biosystems, Boston, MA, USA). Nucleotides primer
sequences of rat origin were used (Table 1). Briefly, 18.2 𝜇L
of master mix, 0.8 𝜇L of primer assay (10x), and 1 𝜇L of
template cDNA (20 ng) were added to each well. After a brief
centrifugation, the PCR plate was subjected to 40 cycles of
the following conditions: (i) PCR activation at 95∘C for 20
seconds, (ii) denaturation at 95∘C for 3 seconds, and (iii)
annealing/extension at 60∘C for 20 seconds. All samples and
controls were run in triplicate on a Mastercycler realplex
system (Eppendorf, NY, USA).The quantitative RT PCR data
were analyzed using a comparative threshold (Ct) method,
and the fold inductions of the samples were compared with
the untreated samples. 𝛽-actin was used as an internal refer-
ence gene to normalize the expression of the target genes.
2.7.Western Blot Analyses of 𝛽-Catenin and COX-2. The fresh
colon tumor tissue disruption and homogenization steps for
extracting proteins were similar to those described for total
RNA extraction. The samples were homogenized in Buffer
RLT using a QIAshredder homogenizer. Protein extrac-
tion was performed using the AllPrep DNA/RNA/Protein
Mini Kit, according to the manufacturer’s protocol (Qiagen,
Duesseldorf, Germany). Next, the protein concentration
was determined by the Bradford assay, according to the
manufacturer’s protocol (Bio-RAD, CA, USA). The protein
(50𝜇g) was separated by 12% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) and transferred
onto a piece of PVDF membrane using transfer buffer
(25mM Tris base, 190mM glycine, and 20% (v/v) methanol,
pH 8.3). After transfer, the PVDF membrane was blocked
at room temperature with blocking solution (25mM Tris
base, 0.3M NaCl, and 5% milk diluent) (Bio-RAD, CA,
USA) for 30 minutes. The membrane was then incubated
overnight with primary antibodies at a 1 : 1000 dilution (𝛽-
catenin rabbit monoclonal antibody and COX-2 rabbit mon-
oclonal antibody from Santa Cruz Biotechnology, CA, USA),
followed by a 1-hour incubation with alkaline phosphatase-
labeled goat anti-mouse secondary antibody (Santa Cruz
Biotechnology, TX, USA) at a 1 : 10000 dilution in Tris-
buffered saline (TBS) and 0.5% Tween 20. Immunodetection
was performed by the addition of a developing solution.
The developing solution for alkaline phosphatase conjugated
antibodies consisted of 10mL alkaline phosphatase buffer
(100mM Tris HCl, 100mMNaCl, and 5mMMgCl
2
; pH 9.5),
33 𝜇L BCIP (0.5 g 5-bromo-4-chloro-3-indolylphosphate-p-
toluidine salt (Fermentas, Lithuania, EU) in 10mL of 100%
(v/v) dimethylformamide (DMF)), and 66𝜇L NBT (0.75 g
nitroblue tetrazolium chloride (Fermentas, Lithuania, EU) in
10mL of 70% (v/v) DMF). The reaction was stopped when
the desired protein band appeared. Densitometric analysis of
band intensities obtained from western blotting experiments
were carried out using ImageJ software (National Institutes of
Health (NIH), USA).
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Table 1: Nucleotide sequence for PCR primers for amplification and sequence-specific detection.
Pair no. Primername Accession no. Oligonucleotides (5
󸀠-3󸀠) sequence Product size (bp)
1 𝛽-catenin NM-001165902 F-ACAGCACCTTCAGCACTCTR-AAGTTCTTGGCTATTACGACA 168
2 COX-2 L25925 F-ACAGGAGAGAAAGAAATGGCTGCAGAGTR-CAGTATTGAGGAGAACAGATGGGATT 198
3 𝛽-actin NM-031144 F-TCACCCACACTGTGCCCATCTATGAR-GTCACGCACGATTTCCCTCTCAGC 180
2.8. Statistical Analysis. Data were expressed as the mean ±
standard deviation (SD) and statistically analyzed using SPSS
version 10, with a one-way ANOVA with Tukey’s test and a
significance level of 𝑃 < 0.05.
3. Results
3.1. Identification of IP
6
. IP
6
was analyzed by reversed-phase
high-performance liquid chromatography (HPLC). HPLC
chromatogramswere comparedwith those of standard phytic
acid. As we reported earlier [9, 23], based on the HPLC
chromatogram data, two peaks were represented as pure
inositol hexaphosphate.
3.2. Body Weight. Figure 1 represents the changes in the rat
body weights during the experiment. Body weights were
compared between all groups (normal, AOM only, AOM +
0.2% (w/v) of IP
6
, AOM + 0.5% (w/v) of IP
6
, and AOM +
1% (w/v) of IP
6
). The plotted graph in Figure 1 shows that
the body weights of all of the rats increased over time. When
comparedwith the normal group, the IP
6
-fed groups (AOM+
0.2% (w/v) of IP
6
, AOM + 0.5% (w/v) of IP
6
, and AOM +
1% (w/v) of IP
6
) showed no significant differences in body
weight, even after 16 weeks of IP
6
treatment. However, there
was a significant (𝑃 < 0.05) difference between the body
weight of the positive control group (AOM only) and the
body weight of the rats in the IP
6
-fed and normal groups.
In addition, the body weight of the AOM-only group was
significantly lower than that of the IP
6
-fed and normal
groups; these results support the expectation that exposure to
the carcinogen AOM would cause weight loss. Additionally,
administration of IP
6
during the early treatment may boost
growth (Figure 1). However, the mechanism is unknown.
These data clearly showed that daily consumption of IP
6
even
for longer duration of treatment was not toxic to normal rats
and also maintained or even increased the body weight of
AOM-treated rats versus normal rats, potentially inhibiting
abnormal growths in the colon, which were further examined
by histopathological analyses.
3.3. Incidence of ACF and Tumors. ACF is a preneoplastic
lesion which can be characterized by clusters of mucosal cells
with an enlarged and thicker layer of epithelia compared
to the surrounding normal crypts. ACF may progress into
polyps, later develop into adenomas, and eventually become
invasive carcinomas [27]. Although not all ACF may develop
into cancer, but all colon cancers arise fromACF as evidenced
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Figure 1: General observation on body weight of experimental rats
throughout the study. IP
6
increases the body weight in all IP
6
-fed
groups relative to the normal group. Groups are normal, AOM only,
AOM+ 0.2% (w/v) of IP
6
, AOM+ 0.5% (w/v) of IP
6
, and AOM+ 1%
(w/v) of IP
6
. (AOM= azoxymethane, IP
6
= inositol hexaphosphate).
by several studies [27]. Jen et al. [28] proposed that only
dysplastic ACF progress to adenoma and adenocarcinoma.
The beneficial effect of various dosages of phytic acid (IP
6
)
(0.2% (w/v), 0.5% (w/v), and 1% (w/v)) on the reduction of
ACF development was further demonstrated. As shown in
Figure 2, the analysis of ACF formation incidence demon-
strated that the administration of rice bran IP
6
significantly
reduced the total number of ACF (𝑃 < 0.05) in all IP
6
-fed
groups in comparison with the untreated rats and AOM-only
group, thereby leading to the inhibition of ACF formation
which may or may not develop into the invasive carcinoma.
Figure 3 summarized the histological analysis of aberrant
crypt foci (ACF) with surrounding normal tissue using H &
E staining. The images (Figure 3) represented the incidence
of ACF taken from group of rats induced with AOM only
(without treatments of IP
6
).
An adenoma is defined as a benign tumor of glandular
origin. Colonic adenoma consists of proliferation on colonic
glands lined by neoplastic colonic epithelium, while an
adenocarcinoma is a malignant tumor originating in glan-
dular epithelium. Colonic adenocarcinoma is composed of
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on AOM-induced colonic aberrant crypt foci
(ACF) in rats. IP
6
decreases the number of ACF in all IP
6
-fed groups
relative to the AOM-only group. Each value expressed as mean ± SD
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aberrant crypt foci, IP
6
= inositol hexaphosphate).
invasive glands lined by pleomorphism and hyperchromatic
epithelium. Figure 4 showed the histopathology of colonic
lesions developed by AOM-induced CRC in rats. The images
(Figure 4) represented the incidence of adenoma and adeno-
carcinoma taken from rats induced with AOM only (without
treatments of IP
6
).
The incidence of adenoma, adenocarcinoma, and total
tumors (adenoma + adenocarcinoma) in different study
groups is summarized in Table 2. The highest incidence of
adenoma, adenocarcinoma, and total tumors occurred in the
AOM-only group. However, administration with IP
6
(0.2,
0.5, and 1% (w/v)) significantly reduced the incidence of
tumors in a dose-dependent manner when compared with
the results of the AOM-only group (no IP
6
treatment) (𝑃 <
0.05). None of the rats in the normal group developed colon
tumor. Additionally, not all rats consist of both adenoma
and adenocarcinoma, namely, total tumors (Table 2), and in
accordance with our previous study which demonstrated that
both adenoma and adenocarcinoma are developed in some of
the rats [9]. Altogether, the administration of IP
6
appeared to
reduce the incidence of adenoma, adenocarcinoma, and total
tumors.
3.4. IP
6
Downregulated the mRNA Levels of 𝛽-Catenin and
COX-2. Our study successfully demonstrates that inhibition
of tumor growth in AOM-induced rat CRC using IP
6
treat-
ment is accompanied by the downregulation of 𝛽-catenin.
Figure 5(a) shows that, compared with the controls, IP
6
-
treated rats expressed less 𝛽-catenin at the mRNA level,
especially for rats treated with the highest concentration of
IP
6
, 1% (w/v). After treatment with 0.2%, 0.5%, and 1% (w/v)
of IP
6
, 𝛽-catenin was significantly downregulated by 0.93-,
0.514-, and 0.385-fold, respectively, demonstrating a dose-
dependent relationship (𝑃 < 0.05).
Moreover, based on the fold changes relative to the
control, IP
6
also significantly inhibited the expression of
COX-2 in AOM-induced rat colon carcinogenesis (𝑃 < 0.05).
As shown in Figure 5(b), after treatmentwith IP
6
(0.2%, 0.5%,
and 1% (w/v)), COX-2 mRNA expression was significantly
downregulated by 0.783-, 0.661-, and 0.426-fold, showing a
dose-dependent relationship (𝑃 < 0.05).
3.5. IP
6
Reduced the Expressions of 𝛽-Catenin and COX-2.
The expression levels of 𝛽-catenin and COX-2 proteins for
the control and experimental group of rats are presented in
Figure 6. The results from the Western blot show that 𝛽-
catenin and COX-2 were both overexpressed in the AOM-
induced rats. As shown in Figure 6(a),𝛽-cateninwas detected
as a 92-kDa band in AOM-induced rat colon carcinogenesis.
Significant reduction in 𝛽-catenin protein expression was
observed after treatment with IP
6
(0.2%, 0.5%, and 1%) by
0.272-, 0.189-, and 0.045-fold relative to the control in a dose-
dependent manner (𝑃 < 0.05).
Furthermore, as shown in Figure 6(b), the immunoreac-
tive bands of COX-2 were detected at 72 kDa (the molecular
weight of COX-2) in AOM-induced rats. Similarly, because
COX-2 expression was inhibited by IP
6
at the mRNA level, it
was also downregulated at the protein level. COX-2 protein
expression in AOM-induced rat colon carcinogenesis was
significantly decreased by 0.38-, 0.102-, and 0.031-fold after
treatment with 0.2%, 0.5%, and 1% (w/v) of IP
6
, respectively,
compared with the control group, thus showing a dose-
dependent relationship (𝑃 < 0.05). All together, these results
showed that the regulation or stability of𝛽-catenin andCOX-
2 protein levels should be affected by IP
6
.
4. Discussion
The primary parameters used in cancer chemoprevention
studies to assess the toxicity of a test compound include
body weight gain profiles. Accordingly, changes in animal
body weight, as a result of IP
6
administration during the 16-
week study period,were assessed to evaluate potential adverse
health effects of the treatment. As mentioned earlier, all of
the IP
6
-fed groups experienced body weight gain that was
similar to the normal group and, therefore, did not show any
significant differences. These results were also observed by
Norazalina et al. [9] who previously studied the anticancer
efficacy of AOM-induced CRC in rats; their results included
the body weights of the rats that were treated with IP
6
from
rice bran. Similar findings were observed in the suppression
of prostate cancer growth for IP
6
-fed mice [26].
A significant reduction in the body weight of AOM-
induced group was observed when compared with the other
groups; the body weights observed for the normal and IP
6
-
fed groups were reliable because, according to Alfin-Slater
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Figure 3: Histological analysis of aberrant crypt foci (ACF) (magnification, 400x). (a) small ACF containing 1 crypt, (b) small ACF containing
2 crypts, (c) medium ACF containing 3 crypts, and (d, e, f) large ACF containing more than 4 crypts. (ACF = aberrant crypt foci).
Table 2: Incidence of tumor of the IP6-treated rats with AOM-induced colon carcinogenesis.
Group no. Treatment No. of rats Incidence (%) of adenoma and/or adenocarcinoma
Adenoma Adenocarcinoma Total
1 Normal 6 0 0 0
2 AOM only 6 4/6 (67%)a 5/6 (83%)b 5/6 (83%)b
3 AOM + 0.2% (w/v) IP6 6 3/6 (50%)
c 3/6 (50%)c 4/6 (67%)d
4 AOM + 0.5% (w/v) IP6 6 1/6 (17%)
e 2/6 (33%)f 3/6 (50%)g
5 AOM + 1% (w/v) IP6 6 1/6 (17%)
e 1/6 (17%)e 2/6 (33%)f
Groups: normal, AOM only, AOM + 0.2% (w/v) of IP6, AOM + 0.5% (w/v) of IP6, AOM + 1% (w/v) of IP6, and (IP6: inositol hexaphosphate, AOM:
azoxymethane). Values in the same column with different superscript indicate significant difference by the Tukey’s test (𝑃 < 0.05). Adenoma is defined as
a benign tumor of glandular origin. Adenocarcinoma is a malignant tumor originating in glandular epithelium. Total tumor consists of both adenoma and
adenocarcinoma in the colon tumor tissue.
andKritchevsky [29], theweight loss that accompanies tumor
development is thought to be associated with a reduction
of not only body fat stores but also body mass. There is
increasing evidence that the tumor directly affects the host’s
proteinmetabolism. Specifically, the protein turnover process
is altered in the cancer-bearing host, and there is a net
loss of nitrogen from nonmalignant tissues because protein
degradation exceeds protein synthesis. Moreover, it is inter-
esting to highlight that in all of the IP
6
-fed groups, even
though all of the rats were initially treatedwith the carcinogen
(AOM), their body weights showed no significant difference
compared with that of the normal rats after 16 weeks of
continuous IP
6
treatment. Thus, the administration of IP
6
appears to have an inverse effect on the reduction in body
weight seen with AOM alone. However, the mechanism
behind this effect is unknown.
The current data shows that the administration of IP
6
in
drinking water suppressed the number of ACF and thereby
leading to the inhibition of tumor incidence in the colons
of the IP
6
-fed groups as compared with the AOM-induced
group. IP
6
has been shown to reduce the number and size of
colon adenomas, which are the precursor lesions of CRC.Our
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Figure 4: Histopathology of colonic lesions developed in rats’ group treated with AOM only. (a) Adenomatous polyps originated from the
colon of a few rats (a and b). The polyps are located in the mucosal layer only. (b) Adenocarcinoma (c and d) showing the invasive gland in
the submucosa and muscular layer (magnification 400x).
study suggests that IP
6
extracted from rice branmight reduce
the formation of tumors in the colon. The tumor inhibition
action of IP
6
has been supported by previous studies, which
showed that the addition of IP
6
to drinking water had a
chemopreventive effect on CRC [9, 30, 31]. Furthermore,
our earlier studies have shown the potential antiproliferative
effects of IP
6
from rice bran on CRC and hepatic cancer in
vitro [32, 33].
Alterations in the APC or 𝛽-catenin gene are regarded as
early critical events during CRC and are therefore considered
to play a gate keeper role in the development of CRC in
both humans and preclinical models [34–36]. Mutations
in the APC or 𝛽-catenin gene were proved to repress the
degradation of the protein and generate 𝛽-catenin accu-
mulations in the cytosol [37, 38]. The excessive 𝛽-catenin
functions as a transcriptional activator when complexed with
members of the T-cell factor (TCF) family of DNA binding
proteins [39, 40]. Furthermore, target genes of 𝛽-catenin
signaling pathway, such as c-myc and cyclin D1, are growth-
promoting genes, suggesting that this pathway is potentially
an oncogenic pathway [41, 42]. Expression of non-p-𝛽-
catenin was elevated in AOM-induced experimental CRC
[43], also colon adenocarcinoma cells [44]. Other natural
compounds have the ability to reduce the expression of
non-p-𝛽-catenin during colon tumorigenesis [43–45]. Our
present study further supported previous reports on the
expression of 𝛽-catenin which was increased while induction
with AOM [46]. We assumed that IP
6
might be involved in
regulation or stability of 𝛽-catenin level in CRC as a previous
study has also reported the role of inositol polyphosphates
in Wnt signaling pathway, by which IP
5
accumulates in
response to Wnt3a, thereby playing an essential component
of signaling of the canonical pathway to the level of 𝛽-catenin
accumulation [47].
Interestingly, we demonstrated that the inhibition of CRC
by IP
6
may be mediated through inactivation of COX-2
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Figure 5: Expression of 𝛽-catenin and COX-2 at the mRNA level in rats with AOM-induced colon carcinogenesis after treatment with IP
6
.
The expressions of 𝛽-catenin and COX-2 mRNA were assessed by quantitative RT PCR. IP
6
downregulates the expression of (a) 𝛽-catenin
and (b) COX-2 in a dose-dependent manner. The results show a typical pattern from the 3 experiments performed. ∗Indicates significant
difference by Tukey’s test (𝑃 < 0.05) relative to their respective control.
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Figure 6: The effect of IP
6
on the protein levels of 𝛽-catenin and COX-2 in rats with AOM-induced colon carcinogenesis. IP
6
decreases the
protein expression of 𝛽-catenin (a) and COX-2 (b) in a dose-dependent manner. Protein expression was normalized to the 𝛽-actin control.
The results show a typical pattern from the 3 experiments performed. ∗Indicates significant difference by Tukey’s test (𝑃 < 0.05) relative to
their respective control.
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gene. The results showed a dose-dependent reduction in the
level of COX-2 in IP
6
-treated rats with AOM-induced CRC.
Although the mechanism underlying how IP
6
modulates the
expression of the COX-2 is still unknown, it is likely that the
downregulation of COX-2 might be the cause of repressed
tumor growth and subsequent tumor cell death. The current
data indicate that oral administration of IP
6
was associated
with a decreased incidence of CRC through reductions in the
number and size of adenomas and invasive carcinomas.These
observations suggest the protective effects of IP
6
against
AOM-induced colon cancer in animal models.
Our data demonstrate that the anticancer action of IP
6
occurs via a reduction in tumor incidence, which subse-
quently leads to tumor suppression and the depletion of
COX-2 and 𝛽-catenin expressions, whereby all of these are
implicated inAOM-induced colon carcinogenesis.These data
further support previous studies suggesting that IP
6
acts as
an anticancer agent by reversing the proliferative effects of
carcinogens [2].
Interestingly, several studies have shown that COX-2
may be regulated by the Wnt/𝛽-catenin signaling pathway
[48–50]. It seems likely that IP
6
may downmodulate Wnt
signaling via the inhibition of 𝛽-catenin, thus reducing levels
of COX-2. This effect was shown by a marked inhibition of
COX-2 expression after treatment with IP
6
. Real-time PCR
determination of the COX-2 mRNA level in IP
6
-treated rats
with AOM-induced CRC indicates that COX-2 is signifi-
cantly downregulated; this effect correlates with the observed
protein levels as well. Therefore, COX-2 expression may be
suppressed via inhibition of Wnt/𝛽-catenin signaling. The
pharmacological inhibition of COX-2 may therefore provide
an effective chemoprotectivemethod against CRC. To further
support this finding and previous studies that correlate
𝛽-catenin with COX-2, we suggest that the underlying
inhibitory mechanism of IP
6
occurs via the suppression of 𝛽-
catenin expression through COX-2 regulation or vice versa.
This correlation at the mRNA and protein levels strongly
supports the reduction of intestinal neoplasia by 𝛽-catenin
and COX-2 inhibitions, suggesting that IP
6
may play a
therapeutic role in CRC andmay contribute to new strategies
in the prevention and treatment of this disease.
5. Conclusion
The observed modulatory influences of rice bran IP
6
at the
level of cell proliferation, by inhibiting 𝛽-catenin and COX-2
during AOM-induced CRC, have not been noted previously
and suggest that the intake of rice bran IP
6
may be used in
future clinical chemopreventive trials to monitor the respon-
siveness of the CRC development to the chemopreventive
agents.
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